document incorporate reference portion abbvie inc proxy statement incorporate reference iii definitive proxy statement file march abbvie inc year end december table content item business item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accounting fee service iv item exhibit financial statement schedule item summary signature item business overview abbvie global researchbase biopharmaceutical company abbvie develop market advanced therapy address world complex disease abbvie product focus treat condition chronic autoimmune disease rheumatology gastroenterology dermatology oncology include blood cancer virology include hepatitis c virus hcv human immunodeficiency virus hiv neurological disorder parkinson disease multiple sclerosis metabolic disease include thyroid disease complication associate cystic fibrosis health condition abbvie pipeline promise new medicine clinical development important medical specialty immunology oncology neurology additional target investment cystic fibrosis woman health abbvie incorporate delaware april january abbvie independent company result distribution abbott laboratories abbott outstanding common stock abbvie abbott shareholder segment abbvie operate business segmentpharmaceutical product note consolidated financial statement sale information relate humira include item management discussion analysis financial condition result operationsresult operation product abbvie portfolio product include broad line therapy address world complex disease humira humira adalimumab biologic therapy administer subcutaneous injection approve treat follow autoimmune disease united states canada mexico collectively north america european union condition principal market rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylose spondylitis north america european union adult crohn disease moderate severe north america european union plaque psoriasis moderate severe chronic north america european union juvenile idiopathic arthritis moderate severe polyarticular north america european union ulcerative colitis moderate severe north america european union axial spondyloarthropathy european union pediatric crohn disease moderate severe north america european union hidradenitis suppurativa moderate severe north america european union pediatric enthesitisrelate arthritis european union noninfectious intermediate posterior panuveitis north america european union humira approve japan treatment intestinal behet disease humira sell numerous market worldwide include japan china brazil australia account approximately abbvie total net revenue abbvie continue work humira formulation delivery enhancement improve convenience overall patient experience text report term abbvie company refer abbvie inc delaware corporation abbvie inc consolidate subsidiary context require oncology product abbvie oncology product target complex difficulttotreat cancer product imbruvica imbruvica ibrutinib firstinclass oral oncedaily therapy inhibit protein call bruton tyrosine kinase btk imbruvica medicine receive fda approval grant breakthrough therapy designation imbruvica therapy receive separate designation imbruvica currently approve treatment adult patient chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll cllsll p deletion mantle cell lymphoma mcl receive prior therapy waldenstrms macroglobulinemia wm marginal zone lymphoma mzl require systemic therapy receive prior anticdbase therapy chronic graft versus host disease cgvhd failure line systemic therapy accelerate approval grant indication base overall response rate continue approval indication contingent verification clinical benefit confirmatory trial venclexta venclexta venetoclax approve treat people cll p deletion receive prior treatment venclexta fdaapprove treatment target bcell lymphoma bcl protein support cancer cell growth overexpresse patient cll venclexta approve eu treatment cll patient p deletion tp mutation unsuitable fail bcell receptor pathway inhibitor treatment cll absence p deletion tp mutation fail chemoimmunotherapy bcell receptor pathway inhibitor virology product abbvie virology product address unmet need patient live hcv hiv hcv product abbvie hcv product viekira pak technivie viekira pak ombitasvir paritaprevir ritonavir tablet dasabuvir tablet alloral shortcourse interferonfree therapy ribavirin treatment adult patient genotype chronic hcv include compensate cirrhosis europe viekira pak market viekirax exviera approve use patient genotype genotype hcv abbvie technivie ombitasvir paritaprevir ritonavir fdaapprove use combination ribavirin treatment adult genotype hcv infection united states mavyretmaviret mavyret glecaprevirpibrentasvir approve united states european union maviret treatment patient chronic hcv genotype infection cirrhosis compensate cirrhosis childpugh indicate treatment adult patient hcv genotype infection previously treat regiman contain hcv nsa inhibitor nsa protease inhibitor week pangenotypic treatment patient cirrhosis new treatment additional virology product abbvie additional virology product include kaletra kaletra lopinavirritonavir market aluvia emerge market prescription antihiv medicine contain protease inhibitor lopinavir ritonavir kaletra antihiv medication treatment maintain viral suppression people hiv norvir norvir ritonavir protease inhibitor indicate combination antiretroviral agent treatment hiv infection synagis synagis palivizumab product market abbvie outside united states protect atrisk infant severe respiratory disease cause rsv form kmetabolicshormone product metabolic hormone product target number condition include testosterone deficiency certain underlying condition exocrine pancreatic insufficiency hypothyroidism product include androgel androgel testosterone gel testosterone replacement therapy male diagnose symptomatic low testosterone certain underlying condition available strength percent percent creon creon pancrelipase pancreatic enzyme therapy exocrine pancreatic insufficiency condition occur patient cystic fibrosis chronic pancreatitis condition synthroid synthroid levothyroxine sodium tablet usp treatment hypothyroidism abbvie right sell androgel creon synthroid united states endocrinology product lupron leuprolide acetate market lucrin lupron depot product palliative treatment advance prostate cancer treatment endometriosis central precocious puberty preoperative treatment patient anemia cause uterine fibroid lupron approve daily subcutaneous injection onemonth threemonth fourmonth sixmonth intramuscular injection product abbvie product include duopa duodopa carbidopa levodopa abbvie levodopacarbidopa intestinal gel treatment advanced parkinson disease market duopa united states duodopa outside united states anesthesia product sevoflurane sell trademark ultane sevorane anesthesia product abbvie sell worldwide human use zinbryta zinbryta daclizumab oncemonthly selfadministere subcutaneous treatment relapse form multiple sclerosis ms approve fda european commission july risk liver damage use zinbryta restrict adult patient relapse form ms inadequate response disease modify therapy dmts treatment dmt contraindicate unsuitable marketing sale distribution capability abbvie utilize combination dedicate commercial resource regional commercial resource distributorship market sell distribute product worldwide abbvie direct primary marketing effort secure prescription recommendation brand product physician key opinion leader health care provider manage care provider example health maintenance organization pharmacy benefit manager hospital state federal government agency example united states department veterans affairs united states department defense important customer abbvie market directly consumer united states company product sell pursuant prescription outside united states abbvie focus marketing effort key opinion leader payer physicians country regulatory body abbvie provide patient support program closely relate product abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse abbvie business significant seasonality abbvie product revenue affect end customer retail buying pattern fluctuation wholesaler inventory level factor united states abbvie distribute pharmaceutical product principally independent wholesale distributor sale directly pharmacie patient wholesale distributor mckesson corporation cardinal health inc amerisourcebergen corporation account substantially abbvie sale united states individual wholesaler account great abbvie gross revenue united states outside united states sale directly customer distributor depend market serve wholesaler purchase product abbvie standard term condition sale certain product comarkete copromote company abbvie single customer customer lose material adverse effect company business material portion abbvie business subject renegotiation profit termination contract election government order generally fill current basis order backlog material abbvie business competition market abbvie product highly competitive abbvie compete researchbase pharmaceutical biotechnology company discover manufacture market sell proprietary pharmaceutical product biologic example humira compete antitnf product competitive product intend treat number disease state abbvie virology product compete available hcv treatment option search technological innovation pharmaceutical product significant aspect competition introduction new product competitor change medical practice procedure result product obsolescence price competitive factor addition substitution generic pharmaceutical product brand pharmaceutical product create competitive pressure abbvie product patent protection new product treatment bring market abbvie competitor cause revenue abbvie product decrease price reduction sale volume decrease biosimilar competition abbvie biologic product affect approval followon biologic know biosimilar biologic add major therapeutic option treatment disease include therapy unavailable inadequate advent biologic raise complex regulatory issue significant pharmacoeconomic concern cost develop produce biologic therapy typically dramatically high conventional small molecule medication expensive biologic medication ongoing treatment chronic disease rheumatoid arthritis inflammatory bowel disease treatment previously untreatable cancer significant investment biologics infrastructure manufacture necessary produce biologic product significant investment market distribution sale organization activity limit number biosimilar competitor united states fda regulate biologics federal food drug cosmetic act public health service act implement regulation enactment federal health care reform legislation march provide pathway approval biosimilar public health service act approval process science biosimilar complex approval process science generic followon version small molecule product add complexity step need ensure safety efficacy biosimilar highly similar original biologic humira ultimate approval fda dependent factor include show biosimilar highly similar original product clinically meaningful difference original product term safety purity potency type datum ordinarily require application similarity include analytical datum study demonstrate chemical similarity animal study include toxicity study clinical study law require biosimilar condition use approve original biologic manufacturing facility meet standard necessary assure biosimilar safe pure potent furthermore law provide biosimilar product determine interchangeable consider substitutable original biologic product intervention health care provider prescribe original biologic product prove biosimilar product interchangeable applicant demonstrate product expect produce clinical result original biologic product give patient product administer patient safety risk potential diminished efficacy alternating switching use interchangeable biosimilar biologic product original biologic product great risk original biologic product switch law continues interpret implement fda result ultimate impact implementation mean remain subject substantial uncertainty european union pathway approval biosimilar exist product come market date mixed impact market share incumbent product significant variation product competitive product number competitive biologic brand product approve humira introduce gain modest share worldwide market abbvie continue face competitive pressure biologic orally administer product intellectual property protection regulatory exclusivity generally approval product entitle certain kind exclusivity applicable intellectual property regulatory regime abbvie intellectual property materially valuable company abbvie seek patent protection available significant market andor country product development united states expiration date patent year filing date give patent relate pharmaceutical product form koften obtain early development process give time need complete clinical trial development activity require regulatory approval length time product launch patent expiration significantly year drug price competition patent term restoration act commonly know hatchwaxman act permit patent holder seek patent extension commonly call patent term restoration patent product process make product regulate federal food drug cosmetic act length patent extension roughly base percent period time file investigational new drug application nda compound submission nda compound plus percent time period nda submission regulatory approval extension exceed year patent term remain regulatory approval exceed year biological product license public health service act similarly eligible term patent restoration pharmaceutical product entitle form legal regulatory exclusivity approval scope length requirement exclusivitie vary united states jurisdictions united states fda approve drug product contain active ingredient previously approve product typically entitle year nonpatent regulatory exclusivity product entitle year exclusivity approval base fdas reliance new clinical study essential approval submit nda applicant nda applicant study product use child fda grant pediatric exclusivity extend day long exist exclusivity patent regulatory relate product product treat condition afflict relatively small population reasonable expectation research development cost recover fda designate pharmaceutical orphan drug grant seven year market exclusivity applicable law regulation dictate scope exclusivity product entitle approval particular country certain instance regulatory exclusivity protect product patent protection long available period time excess patent protection possible estimate product development total period scope exclusivity entitle regulatory approval obtain give length time require complete clinical development pharmaceutical product period exclusivity achieve individual case expect exceed minimum year maximum year estimate consider factor difficulty recreate manufacturing process particular product proprietary knowledge delay introduction generic followon product expiration applicable patent regulatory exclusivity period biologic entitle exclusivity biologic price competition innovation act pass march title vii patient protection affordable care act law provide pathway approval biosimilar follow expiration year exclusivity innovator biologic potential additional dayextension term conduct pediatric study biologic eligible orphan drug exclusivity discuss law include extensive process innovator biologic biosimilar manufacturer litigate patent infringement validity enforceability european union create pathway approval biosimilar publish guideline approval certain biosimilar product complex nature biologic biosimilar product lead great regulatory scrutiny rigorous requirement approval followon biosimilar product small molecule generic pharmaceutical product reduce effect biosimilar sale innovator biologic compare sale erosion cause generic version small molecule pharmaceutical product abbvie own license right substantial number patent patent application abbvie license own patent portfolio thousand patent family include united states patent application andor issue patent contain nonunite state counterpart patent application patent application include patent expire period late aggregate believe material importance operation abbvie business abbvie believe single patent license trademark relate group patent license trademark relate adalimumab sell trademark humira material relation company business united states composition matter compound patent cover adalimumab expire december equivalent european union patent expect expire majority european union country october united states noncomposition matter patent cover adalimumab expire early addition follow patent license trademark significant relate ibrutinib sell trademark imbruvica relate ombitasvirparitaprevirritonavir dasabuvir sell trademark viekira pak viekirax exviera holkira pak relate glecaprevir pibrentasvir sell trademark mavyret maviret relate testosterone sell trademark androgel united states composition matter patent cover ibrutinib expect expire united states composition matter patent cover ombitasvir paritaprevir dasabuvir expect expire respectively united states composition matter patent cover glecaprevir pibrentasvir expect expire abbvie rely circumstance trade secret protect technology trade secret difficult protect abbvie seek protect technology product candidate confidentiality agreement employee consultant advisor contractor collaborator agreement breached abbvie adequate remedy breach addition abbvie trade secret know independently discover competitor extent abbvie employee consultant advisor contractor collaborator use intellectual property own work company dispute arise right relate result knowhow invention license arrangement addition independent effort develop market product abbvie enter arrangement license arrangement strategic alliance copromotion arrangement codevelopment comarkete agreement joint venture license arrangement typically include term condition nonrefundable upfront license fee milestone payment royalty andor profit sharing obligation note license acquisition arrangementsother licensing acquisition activity consolidated financial statement include item financial statement supplementary datum party agreement abbvie agreement party process development product distribution analytical service manufacture certain product abbvie procure certain product service limit number supplier case single supply source addition abbvie agreement party active pharmaceutical ingredient product manufacturing formulation development service fill finish packaging service transportation distribution logistic service certain product abbvie believe manufacture relate agreement material abbvie business substantially dependent individual agreement case abbvie maintain alternate supply relationship utilize undue disruption manufacturing process party fails perform contractual obligation abbvie maintain sufficient inventory product minimize impact supply disruption abbvie party certain collaboration arrangement discuss note license acquisition arrangementsother licensing acquisition activity consolidated financial statement include item financial statement supplementary data source availability raw material abbvie purchase ordinary course business raw material supply essential operation numerous supplier world addition certain medical device component necessary manufacture abbvie product provide unaffiliated party supplier abbvie experience recent significant availability problem supply shortage impact fulfillment product demand research development activity abbvie make significant investment research development numerous compound clinical development include potential treatment complex lifethreatening disease abbvie ability discover develop new compound enhance company use integrate discovery development project team include chemist biologist physician pharmacologist work compound team abbvie partner party biotechnology company pharmaceutical company academic institution identify prioritize promise new treatment complement enhance abbvie exist portfolio research development process generally begin discovery research focus identification molecule desire effect give disease preclinical testing identify compound prove successful compound move clinical development generally include follow phase phase involve human test small number healthy volunteer patient assess safety tolerability potential dosing phase test drug efficacy disease relatively small group patient phase test drug demonstrate favorable result early phase significantly large patient population demonstrate efficacy safety base regulatory criterion clinical trial development phase provide datum require prepare submit nda biological license application bla submission regulatory approval fda similar government agency outside united states specific requirement eg scope clinical trial obtain regulatory approval vary different country geographic region research development process discovery new drug launch typically take year long research development new pharmaceutical product significant inherent uncertainty guarantee molecule receive regulatory approval require launch new drug indication addition development new product new formulation research development project include phase trial call postmarkete study project clinical trial design conduct collect additional datum parameter benefit risk approve drug abbvie spend approximately billion billion billion research discover develop new product indication process improve exist product process expense consist primarily salary relate expense personnel license fee consulting payment contract research clinical drug supply manufacturing cost laboratory equipment facility clinical trial cost collaboration fee expense regulationdiscovery clinical development united states secure approval market new pharmaceutical product united states require substantial effort financial resource take year complete applicant complete preclinical test submit protocol fda commence clinical trial clinical trial intend establish safety efficacy pharmaceutical product typically conduct sequential phase phase overlap combine require clinical testing successful result submit fda form nda bla request approval market product indication fda review nda bla determine product safe effective intended use manufacturing compliant current good manufacturing practice cgmp nda bla receive approval applicant comply postapproval requirement example holder approval report adverse reaction provide update safety efficacy information comply requirement concern advertise promotional material activity quality control manufacturing procedure continue conform cgmp approval certain change manufacturing procedure finish product include nda bla approve fda fda periodically inspect manufacture facility assess compliance cgmp impose extensive procedural record keeping requirement addition condition approval fda require postmarkete testing surveillance assess monitor product safety efficacy commercialization require additional clinical trial patient registrie additional work chemistry manufacturing control postapproval regulatory obligation cost comply obligation expand future outside united states abbvie subject similar regulatory requirement outside united states abbvie obtain approval clinical trial application product applicable regulatory authority commence clinical trial marketing product approval requirement process country vary time require obtain approval long shorter require fda approval united states example abbvie submit marketing authorization european union centralize decentralize procedure centralize procedure mandatory approval biotechnology product pharmaceutical product provide single marketing authorization valid european union member state centralized procedure single marketing authorization application submit european medicine agency ema agency evaluate application make recommendation european commission make final determination approve application decentralize procedure provide mutual recognition individual national approval decision available product subject centralized procedure japan application approval new product pharmaceutical medical device agency pmda bridge study demonstrate nonjapanese clinical datum apply japanese patient require complete comprehensive review pmda report ministry health labour welfare approve deny application regulatory process emerge market continue evolve emerge market include asia generally require regulatory approval obtain large develop market united states europe country begin complete regulatory review process country require local clinical study conduct order obtain regulatory approval country requirement govern conduct clinical trial product licensing vary addition postapproval regulatory obligation adverse event report cgmp compliance generally apply vary country example marketing authorization grant european union periodic safety report submit pharmacovigilance measure require risk management plan regulationcommercialization distribution manufacturing manufacture marketing sale promotion distribution abbvie product subject comprehensive government regulation government regulation national regional federal state local agency united states country address matter inspection control research laboratory procedure clinical investigation product approval manufacturing labeling packaging marketing promotion pricing reimbursement sampling distribution quality control postmarkete surveillance record keeping storage disposal practice abbvie operation affect trade regulation country limit import raw material finish product law regulation seek prevent corruption bribery marketplace include united states foreign corrupt practice act united kingdom bribery act provide guidance corporate interaction government official require safeguard protection personal datum addition abbvie subject law regulation pertain health care fraud abuse include state federal antikickback false claim law united states prescription drug manufacturer abbvie subject taxis application product user establishment fee compliance law regulation costly materially affect abbvie business effect health care regulation substantially increase time difficulty cost incur obtain maintain approval market newly develop exist product abbvie expect compliance regulation continue require significant technical expertise capital investment ensure compliance failure comply delay release new product result regulatory enforcement action seizure recall product suspension revocation authority necessary product production sale civil criminal sanction include fine penalty addition regulatory initiative abbvie business affect ongoing study utilization safety efficacy outcomes health care product component regularly conduct industry participant government agency study question utilization safety efficacy previously market product case study result future result discontinuance limitation marketing product domestically worldwide rise claim damage person believe injure result use access human health care product continue subject investigation action governmental agency legislative body private organization united states country major focus cost containment effort reduce health care cost private sector notably health care payer provider institute cost reduction containment measure abbvie expect insurer provider continue attempt reduce cost health care product outside united states country control price health care product directly indirectly reimbursement payment pricing coverage limitation compulsory license budgetary pressure united states country heighten scope severity pricing pressure abbvie product foreseeable future united states specifically federal law require pharmaceutical manufacturer pay certain statutorilyprescribe rebate state medicaid programs prescription drug reimburse state medicaid plan effort state seek additional rebate affect abbvie business similarly veteran health care act prerequisite participation medicaid federal health care program require manufacturer extend additional discount pharmaceutical product federal agency include united states department veterans affairs department defense public health service entity institution addition recent legislative change require similarly discount price offer tricare program beneficiary veterans health care act establish b drug discount program require pharmaceutical manufacturer provide product reduce price designate health care entity facilities united states states generic substitution legislation require permit dispense pharmacist substitute different manufacturer generic version pharmaceutical product prescribe addition federal government follows diagnosisrelate group drg payment system certain institutional service provide form kmedicare medicaid implement prospective payment system pps service deliver hospital outpatient nursing home home health setting drg pps entitle health care facility fix reimbursement base diagnosis andor procedure actual cost incur patient treatment increase incentive facility limit control expenditure health care product medicare reimburse b drug base average sale price plus certain percentage account physician administration cost reduce hospital outpatient set medicare enter contract private plan negotiate price patientadministere medicine deliver patient protection affordable care act health care education reconciliation act affordable care act abbvie pay fee relate pharmaceutical sale government program addition abbvie provide discount brand prescription drug sell patient fall medicare coverage gap donut hole affordable care act include provision know physician payment sunshine act require manufacturers drug biologics cover medicare medicaid record transfer value physician teach hospital report datum center medicare medicaid services subsequent public disclosure similar reporting requirement enact state level united states increase number country worldwide adopt consider similar law require disclosure interaction health care professional failure report appropriate datum result civil criminal fine andor penalty abbvie expect debate continue government level worldwide marketing availability method delivery payment health care product service abbvie believe future legislation regulation market serve affect access health care product service increase rebate reduce price rate price increase health care product service change health care delivery system create new fee obligation pharmaceutical industry require additional reporting disclosure possible predict extent abbvie health care industry general affect matter discuss abbvie subject corporate integrity agreement cia enter abbott require enhancement abbvie compliance program contain report obligation include disclosure financial payment doctor abbvie fail comply cia office inspector general united states department health human service impose monetary penalty exclude abbvie federal health care program include medicare medicaid european union european union adopt directive legislation govern label advertising distribution supply pharmacovigilance marketing pharmaceutical product legislation provide mandatory standard european union permit member states supplement standard additional regulation european government regulate pharmaceutical product price control national health care system fund large cost product consumer result patient unlikely use pharmaceutical product reimburse government european country government regulate price new product launch subsequent launch direct price control reference pricing recent year country impose new additional cost containment measure pharmaceutical product difference national pricing regime create price differential european union lead significant parallel trade pharmaceutical product government promote generic substitution mandate permit pharmacist substitute different manufacturer generic version pharmaceutical product prescribe permit mandate health care professional prescribe generic version certain circumstance addition government use reimbursement list limit pharmaceutical product eligible reimbursement national health care systems japan japan national health insurance system maintain drug price list specify pharmaceutical product eligible reimbursement ministry health labour welfare set price product list government generally introduce price cut round year mandate price decrease specific product new product judge innovative useful indicate pediatric use target orphan small population disease eligible pricing premium government promote use generic available emerge market emerge market step reduce pharmaceutical product price case direct price control promotion generic alternative brand pharmaceutical abbvie market product worldwide certain product local nature variation product line meet local regulatory requirement certain additional risk inherent conduct business outside united states include price currency exchange control change currency exchange rate limitation participation local enterprise expropriation nationalization governmental action environmental matter abbvie believe operation comply material respect applicable law regulation concern environmental protection regulation federal state environmental law impose stringent limitation emission discharge environment manufacturing operation abbvie capital expenditure pollution control approximately million operating expenditure approximately million capital expenditure pollution control estimate approximately million operating expenditure estimate approximately million abbott identify potentially responsible party investigation andor remediation location united states include puerto rico comprehensive environmental response compensation liability act commonly know superfund location transfer abbvie connection separation distribution abbvie party investigation remediations abbott engage remediation site transfer abbvie connection separation distribution cooperation environmental protection agency similar agency feasible predict certainty final cost relate investigation remediation activity abbvie believe cost expenditure maintain compliance applicable law regulation concern environmental protection material adverse effect company financial position cash flow result operation employee abbvie employ approximately person january outside united states abbvie employee represent union work council abbvie believe good relation employee internet information copy abbvie annual report quarterly report form q current report form k amendment report file furnish pursuant section security exchange act available free charge abbvie investor relation website wwwabbvieinvestorcom soon reasonably practicable abbvie electronically file material furnish securities exchange commission sec abbvie corporate governance guideline outline directorship qualification code business conduct charters abbvie audit committee compensation committee nomination governance committee public policy committee available abbvie investor relation website wwwabbvieinvestorcom item risk factor carefully consider follow risk information evaluate abbvie abbvie common stock follow risk materially adversely affect abbvie result operation financial condition cash flow risk factor generally separate group risk relate abbvie business risk relate abbvie common stock base information currently know abbvie believe follow information identify significant risk factor affect category risk risk uncertainty abbvie face limit set forth risk factor describe order importance probability occurrence additional risk uncertainty presently know abbvie abbvie currently believe immaterial adversely affect business addition past financial performance reliable indicator future performance historical trend anticipate result trend future period follow risk uncertainty develop actual event event material adverse effect abbvie business result operation financial condition cash flow case trading price abbvie common stock decline form krisk relate abbvie business expiration loss patent protection license adversely affect abbvie future revenue operate earning abbvie rely patent trademark intellectual property protection discovery development manufacturing sale product particular patent protection aggregate important abbvie marketing pharmaceutical product united states major market outside united states patent cover abbvie product normally provide market exclusivity important profitability abbvie product patent certain product expire abbvie face competition lower price generic product expiration loss patent protection product typically follow promptly substitute significantly reduce sale product short time abbvie competitive position compromise generic material adverse effect abbvie business result operation addition proposal emerge time time legislation encourage early rapid approval generic drug proposal enact law increase impact generic competition abbvie principal patent trademark describe great detail item businessintellectual property protection regulatory exclusivity item management discussion analysis financial condition result operationsresult operation litigation patent describe item legal proceeding united states composition matter patent humira abbvie large product worldwide net revenue approximately billion expire december equivalent european union patent expect expire majority european union country october humira biologic biologic readily substitute uncertain impact loss patent protection sale humira abbvie major product lose patent protection early expect adversely affect abbvie future revenue operate earning party government authority challenge seek invalidate circumvent abbvie patent patent application example manufacturer generic pharmaceutical product file continue file abbreviate new drug application fda seek market generic form abbvie product prior expiration relevant patent own license abbvie assert patent invalid unenforceable andor infringe addition petitioner file continue file challenge validity abbvie patent leahysmith america invents act create inter parte review post grant review procedure challenge patent validity administrative proceeding united states patent trademark office challenge abbvie intellectual property come business government challenge intellectual property right example court decision potential legislation relate patent legislation biosimilar regulatory initiative result erosion intellectual property protection addition certain government outside united states indicate compulsory license patent seek domestic policy basis national emergency hivaid trigger compulsory license diminish eliminate sale profit jurisdiction negatively affect abbvie result operation abbvie normally respond challenge vigorously defend patent include file patent infringement lawsuit patent litigation administrative proceeding challenge abbvie patent costly unpredictable deprive abbvie market exclusivity patent product extent abbvie intellectual property successfully challenge circumvent extent intellectual property allow abbvie compete effectively abbvie business suffer extent country enforce abbvie intellectual property right require compulsory licensing abbvie intellectual property abbvie future revenue operate earning reduce party intellectual property prevent abbvie selling product material adverse effect abbvie future profitability financial condition party claim abbvie product infringe intellectual property resolve intellectual property infringement claim costly time consuming require abbvie enter license agreement abbvie guarantee able obtain license agreement commercially reasonable term successful claim patent intellectual property infringement subject abbvie significant damage injunction prevent manufacture sale use affect abbvie product product event material adverse effect abbvie profitability financial condition significant event adversely affect humira revenue material negative impact abbvie result operation cash flow humira account approximately abbvie total net revenue significant event adversely affect humira revenue material adverse impact abbvie result operation cash flow event include loss patent protection humira commercialization biosimilar humira discovery previously unknown effect impair efficacy increase competition introduction new effective expensive treatment discontinuation removal market humira reason abbvie research development effort succeed develop marketing commercially successful product technology cause revenue profitability decline remain competitive abbvie continue launch new product new indication andor brand extension exist product launch generate revenue sufficient cover substantial research development cost replace revenue profitable product lose displace compete product therapy failure material adverse effect abbvie revenue profitability accordingly abbvie commit substantial effort fund resource research development ongoing substantial expenditure assurance effort commercially successful high rate failure biopharmaceutical industry inherent research development new product failure occur point research development process include significant fund invest product appear promise development fail reach market numerous reason include failure demonstrate effectiveness safety concern superior safety efficacy compete therapy failure achieve positive clinical preclinical outcome current standard care inability obtain necessary regulatory approval delay approval new product new indication limited scope approve use excessive cost manufacture failure obtain maintain intellectual property right infringement intellectual property right decision research study early development process pharmaceutical product candidate affect marketing strategy candidate receive approval detailed study demonstrate additional benefit help marketing consume time resource delay submit pharmaceutical product candidate approval abbvie guarantee proper balance speed testing respect pharmaceutical product candidate decision area adversely affect abbvie future result operation abbvie successfully develop market new product enhancement exist product quickly render obsolete change clinical preference change industry standard competitor innovation abbvie innovation accept quickly marketplace exist clinical practice uncertainty thirdparty reimbursement abbvie state certainty product development launch able develop license acquire compound product product commercially successful failure launch successful new product new indication exist product cause abbvie product obsolete cause abbvie revenue operate result suffer portion abbvie nearterm pharmaceutical pipeline rely collaboration party adversely affect development sale product abbvie depend alliance pharmaceutical biotechnology company portion product nearterm pharmaceutical pipeline example abbvie collaborate roche hold ag develop commercialize nextgeneration bcl inhibitor venclexta venetoclax patient relapsedrefractory chronic lymphocytic leukemia abbvie investigate efficacy additional indication failure party meet contractual regulatory obligation abbvie disruption relationship abbvie party adverse effect abbvie pharmaceutical pipeline business addition abbvie collaborative relationship research development extend year rise dispute relative right obligation revenue abbvie collaboration partner include ownership intellectual property associate right obligation result loss intellectual property right protection delay development sale potential pharmaceutical product lead lengthy expensive litigation administrative proceeding arbitration form kbiologic carry unique risk uncertainty negative impact future result operation successful discovery development manufacturing sale biologic long expensive uncertain process unique risk uncertainty biologic example access supply necessary biological material cell line limit governmental regulation restrict access regulate transport use material addition development manufacturing sale biologic subject regulation complex extensive regulation applicable pharmaceutical product manufacture biologic especially large quantity complex require use innovative technology manufacturing require facility specifically design validate purpose sophisticated quality assurance quality control procedure biologic frequently costly manufacture production input derive live animal plant material biologic synthetically failure successfully discover develop manufacture sell biologicsincluding humiracould adversely impact abbvie business result operation abbvie biologic product subject competition biosimilar biologics price competition innovation act create framework approval biosimilar united states allow competitor reference datum biologic product approve europe european commission grant marketing authorization biosimilar pursuant set general product classspecific guideline biosimilar approval issue past year addition company develop biosimilar country compete abbvie biologic product competitor able obtain marketing approval biosimilar reference abbvie biologic product abbvie product subject competition biosimilar attendant competitive pressure consequence expiration successful challenge abbvie applicable patent right trigger competition product assume relevant exclusivity period expire result abbvie face litigation administrative proceeding respect validity andor scope patent relate biologic product new product technological advance abbvie competitor negatively affect abbvie result operation abbvie compete researchbase pharmaceutical biotechnology company discover manufacture market sell proprietary pharmaceutical product biologic example humira compete antitnf product competitive product intend treat number disease state abbvie virology product compete available hepatitis c treatment option competitor introduce new product develop technological advance compete abbvie product therapeutic area immunology virologyliver disease oncology neuroscience abbvie predict certainty timing impact introduction competitor new product technological advance compete product safer effective effectively market sell low price superior performance feature abbvie product negatively impact abbvie business result operation manufacture abbvie product highly exact complex process abbvie supplier encounter problem manufacture abbvie product abbvie business suffer manufacture abbvie product highly exact complex process strict regulatory requirement problem arise manufacturing variety reason include equipment malfunction failure follow specific protocol procedure problem raw material delay relate construction new facility expansion exist facility include intended support future demand abbvie product change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation inhibit continuous supply manmade natural disaster environmental factor problem arise production batch product batch product discard abbvie experience product shortage incur add expense thing lead increase cost lose revenue damage customer relation time expense spend investigate cause depend cause similar loss respect batch product problem discover product release market recall product liability cost incur abbvie use number product pharmaceutical biologic manufacturing process source single supplier interruption supply product adversely affect abbvie business result operation abbvie use number product pharmaceutical biologic manufacturing process source single supplier failure singlesource supplier fulfill contractual obligation timely manner result regulatory noncompliance physical disruption manufacturing site impair abbvie ability deliver product customer timely competitive basis adversely affect abbvie business result operation find alternative supplier significant time involve significant expense nature product need obtain regulatory approval abbvie guarantee able reach agreement alternative provider regulatory authority approve abbvie use alternative abbvie carry business interruption insurance provide degree protection case failure singlesource supplier significant safety efficacy issue arise abbvie product material adverse effect abbvie revenue financial condition pharmaceutical product receive regulatory approval base datum obtain control clinical trial limit duration follow regulatory approval product long period time patient investigator conduct additional extensive study new safety efficacy issue report new scientific information available include result postmarkete phase trial government change standard safety efficacy labeling abbvie require amend condition use product example abbvie voluntarily provide require provide update information product label narrow approve indication reduce product market acceptance safety efficacy issue abbvie product arise sale product halt abbvie regulatory authority safety efficacy issue affect supplier competitor product reduce market acceptance abbvie product new data abbvie product product similar product negatively impact demand abbvie product real perceive safety issue uncertainty efficacy case result product withdrawal furthermore new data information include information product misuse lead government agency professional society practice management group organization involve disease publish guideline recommendation relate use abbvie product use related therapy place restriction sale guideline recommendation lead low sale abbvie product abbvie subject product liability claim lawsuit adversely affect business result operation ordinary course business abbvie subject product liability claim lawsuit allege abbvie product product company promote result result unsafe condition injury patient product liability claim lawsuit safety alert product recall regardless ultimate outcome material adverse effect abbvie business result operation reputation ability attract retain customer consequence include additional cost decrease market share product question low income exposure claim product liability loss selfinsure abbvie subject costcontainment effort pricing pressure cause reduction future revenue operate earning change term rebate chargeback programs common pharmaceutical industry material adverse effect abbvie operation costcontainment effort government private organization describe great detail item businessregulationcommercialization distribution manufacturing extent cost containment effort offset great demand increase patient access health care factor abbvie future revenue operate earning reduce united states european union country abbvie business experience downward pressure product pricing pressure increase future abbvie subject increase public legislative pressure respect pharmaceutical pricing united states practice manage care group institutional governmental purchaser united states federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act contribute pricing pressure potential continue form kchange health care system united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result additional pricing pressure numerous major market worldwide government play significant role fund health care service determine pricing reimbursement pharmaceutical product consequently market abbvie subject government decisionmake budgetary action respect product particular european country ongoing governmentmandate price reduction pharmaceutical product abbvie anticipate continue pricing pressure europe difference country pricing regulation lead thirdparty crossborder trading abbvie product result reduction future revenue operate earning rebate relate government program feeforservice medicaid medicaid manage care program arise law regulation abbvie predict additional government initiative contain health care cost factor lead new modify regulatory requirement include high incremental rebate discount rebate discount program arise contractual agreement private payer factor include market factor ability private payer control patient access product provide payer leverage negotiate high additional rebate discount material adverse effect abbvie operation abbvie subject numerous governmental regulation costly comply regulation develop compliant product process abbvie product subject rigorous regulation numerous international supranational federal state authority describe item businessregulationdiscovery clinical development process obtain regulatory approval market pharmaceutical product costly time consume approval grant future product additional indication use exist product timely basis delay receipt failure obtain approval future product new indication use result delay realization product revenue reduction revenue substantial additional cost addition abbvie guarantee remain compliant applicable regulatory requirement approval obtain product requirement include thing regulation manufacturing practice product label advertising postmarkete reporting include adverse event report field alert manufacturing quality concern abbvie incur expense spend time effort ensure compliance complex regulation possible regulatory action result substantial modification abbvie business practice operation refund recall seizures abbvie product total partial shutdown production abbvie supplier facility abbvie supplier remedy allege violation inability obtain future approval withdrawal suspension current product market event disrupt abbvie business material adverse effect business result operation law regulation affect government benefit program impose new obligation abbvie require change business practice restrict operation future health care industry subject federal state international law regulation pertain government benefit program reimbursement rebate price reporting regulation health care fraud abuse united states law include antikickback false claim law medicaid rebate statute veterans health care act individual state law relate pricing sale marketing practice violation law punishable criminal andor civil sanction include instance substantial fine imprisonment exclusion participation federal state health care program include medicare medicaid veterans administration health program law regulation broad scope subject change evolving interpretation require abbvie incur substantial cost associate compliance alter sale marketing practice addition violation law allegation violation disrupt abbvie business result material adverse effect business result operation abbvie subject increase monetary penalty andor sanction include exclusion federal health care program fail comply term resolution department justice investigation sale marketing activity depakote abbott settle united states federal state investigation sale marketing activity depakote plead guilty misdemeanor violation food drug cosmetic act agree pay approximately million criminal fine forfeiture approximately million resolve civil claim submit term probation term probation end january abbvie satisfy probation condition abbvie violate remain term plea agreement face additional monetary sanction remedy court deem appropriate addition abbott enter fiveyear cia office inspector general united states department health human service oig effective date cia october obligation cia transfer fully bind abbvie cia require enhancement abbvie compliance program fulfillment report monitoring obligation management certification resolution abbvie board director requirement compliance requirement settlement impose additional cost burden abbvie include form employee training party review compliance monitoring report obligation management attention abbvie fail comply cia oig impose monetary penalty exclude abbvie federal health care program include medicare medicaid abbvie abbott subject party claim shareholder lawsuit connection settlement abbvie require indemnify portion abbott cost international nature abbvie business subject additional business risk cause revenue profitability decline abbvie business subject risk associate business internationally include emerge market net revenue outside united states approximately abbvie total net revenue risk associate abbvie operation outside united state include fluctuation currency exchange rate change medical reimbursement policy program multiple legal regulatory requirement subject change restrict abbvie ability manufacture market sell product differ local product preference product requirement trade protection measure import export licensing requirement difficulty establish staffing manage operation differ labor regulation potentially negative consequence change interpretation tax law political economic instability include sovereign debt issue price currency exchange control limitation participation local enterprise expropriation nationalization governmental action inflation recession fluctuation interest rate potential deterioration economic position credit quality certain nonus country include europe latin america potential penalty adverse consequence violation anticorruption antibribery similar law regulation include united states foreign corrupt practice act united kingdom bribery act event contemplate risk individually aggregate material adverse effect abbvie revenue profitability abbvie effectively profitably commercialize imbruvica abbvie revenue financial condition adversely affect abbvie effectively profitably commercialize imbruvica create meeting continue market demand achieve market acceptance generating product sale ensure active pharmaceutical ingredient imbruvica finish product manufacture sufficient quantity compliance requirement fda similar foreign regulatory agency acceptable quality pricing meet commercial demand ensure entire supply chain efficiently consistently deliver imbruvica abbvie customer commercialization form kimbruvica successful thing unexpected challenge competitor new safety issue concern report impact narrow approve indication relative price imbruvica compare alternative treatment option change label imbruvica restrict marketing commercialization imbruvica unsuccessful abbvie ability generate revenue product sale realize anticipate benefit merger pharmacyclic adversely affect abbvie acquire business license right technology product form alliance dispose asset cause incur significant expense negatively affect profitability abbvie pursue acquisition technology licensing arrangement strategic alliance dispose asset business strategy abbvie complete transaction timely manner costeffective basis realize expect benefit abbvie successful making acquisition product technology acquire successful require significantly great resource investment originally anticipate abbvie able integrate acquisition successfully exist business incur assume significant debt unknown contingent liability abbvie experience negative effect report result operation acquisition dispositionrelate charge amortization expense relate intangible charge impairment longterm asset effect cause deterioration abbvie credit rating result increase borrowing cost interest expense additionally change abbvie structure operation revenue cost efficiency result major transaction acquisition divestiture merger alliance restructuring strategic initiative result great expect cost long expect complete encounter difficulty include need regulatory approval appropriate abbvie dependent wholesale distributor distribution product united states accordingly result operation adversely affect encounter financial difficulty wholesale distributor mckesson corporation cardinal health inc amerisourcebergen corporation account substantially abbvie sale united states significant wholesale distributor encounter financial difficulty distributor decrease business abbvie abbvie unable collect amount distributor owe timely basis negatively impact abbvie business result operation abbvie debt obligation adversely affect business ability meet obligation debt abbvie incur intend incur important consequence abbvie investor consequence include thing require portion abbvie cash flow operation interest payment debt reduce cash flow available fund capital expenditure corporate purpose grow abbvie business extent abbvie incur additional indebtedness risk increase addition abbvie cash flow operation sufficient repay outstanding debt abbvie able borrow money sell asset raise fund acceptable term refinance debt abbvie need additional financing future meet capital need opportunistic acquisition financing available favorable term abbvie need seek additional financing general corporate purpose example need increase investment research development activity need fund acquisition abbvie unable obtain desire additional financing term favorable abbvie lose investment grade credit rating adequate fund available acceptable term abbvie unable fund expansion successfully develop enhance product respond competitive pressure negatively affect abbvie business abbvie raise additional fund issue debt enter credit facility subject limitation operation restrictive covenant failure comply covenant adversely affect abbvie business abbvie depend information technology failure system adversely affect abbvie business abbvie rely sophisticated information technology system operate business system potentially vulnerable malicious intrusion random attack loss datum privacy breakdown datum privacy security breach employee cause sensitive datum include intellectual property trade secret personal information belong abbvie patient customer business partner expose unauthorized person public abbvie invest protection datum information technology monitor system ongoing basis assurance effort prevent breakdown breaches abbvie information technology system adversely affect abbvie business factor material adverse effect abbvie profitability financial condition factor affect abbvie result operation cash flow financial condition include change interpretation law regulation include change accounting standard taxation requirement product marketing application standard environmental law difference fair value measurement asset liability actual value particularly pension postemployment benefit stockbase compensation intangible goodwill contingent liability litigation contingent consideration absence record record minimum compare actual change rate inflation include cost raw material commodity supply interest rate market value abbvie equity investment performance investment hold employee benefit trust change creditworthiness counterpartie transact business provide service abbvie employee benefit trust change ability party provide information technology account human resource payroll outsource service abbvie meet contractual obligation abbvie change business economic political condition include war political instability terrorist attack threat future terrorist activity relate military action natural disaster cost availability insurance forego event labor dispute strike slowdown form labor union activity pressure thirdparty interest group risk relate abbvie common stock abbvie guarantee timing payment dividend common stock abbvie expect pay regular cash dividend time declaration payment future dividend stockholder fall discretion abbvie board director board decision payment dividend depend factor abbvie financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board deem relevant information item market registrant common equity relate stockholder matter issuer purchase equity security abbvie ability pay dividend depend ongoing ability generate cash operation access capital market abbvie guarantee continue pay dividend future abbvie stockholder percentage ownership abbvie dilute future future stockholder percentage ownership abbvie dilute equity issuance capital market transaction equity awards abbvie grant abbvie director officer employee acquisition purpose abbvie employee option purchase share common stock result conversion abbott stock option abbvie stock option abbvie anticipate compensation committee grant additional stock option stockbase award employee award dilutive effect abbvie earning share adversely affect market price abbvie common stock time time abbvie issue additional option stockbase award employee abbvie employee benefit plan form kin addition abbvie amend restate certificate incorporation authorize abbvie issue approval abbvie stockholder class series prefer stock designation power preference relative participate optional special right include preference abbvie common stock respect dividend distribution abbvie board director generally determine term class series prefer stock dilute voting power reduce value abbvie common stock example abbvie grant holder prefer stock right elect number abbvie director event happen specify event right veto specify transaction similarly repurchase redemption right liquidation preference abbvie assign holder prefer stock affect residual value common stock certain provision abbvie amend restate certificate incorporation amend restate bylaw delaware law prevent delay acquisition abbvie decrease trading price abbvie common stock abbvie amend restate certificate incorporation amend restate bylaw contain delaware law contain provision intend deter coercive takeover practice inadequate takeover bid make practice bid unacceptably expensive bidder encourage prospective acquiror negotiate abbvie board director attempt hostile takeover provision include inability abbvie stockholder special meeting division abbvie board director class director class serve stagger threeyear term provision stockholder remove director cause ability abbvie director stockholder fill vacancy abbvie board director requirement affirmative vote stockholder hold abbvie voting stock require amend certain provision abbvie amend restate certificate incorporation abbvie amend restate bylaw relate number term election abbvie director fill board vacancy call special meeting stockholder director officer indemnification provision addition section delaware general corporation law provide subject limited exception person acquire affiliated person acquire outstanding voting stock delaware corporation shall engage business combination corporation include merger consolidation acquisition additional share threeyear period follow date person affiliate holder corporation outstanding voting stock abbvie believe provision protect stockholder coercive unfair takeover tactic require potential acquiror negotiate abbvie board director provide abbvie board director time assess acquisition proposal provision intend company immune takeover provision apply offer consider beneficial stockholder delay prevent acquisition abbvie board director determine good interest abbvie abbvie stockholder provision prevent discourage attempt remove replace incumbent director cautionary statement forwardlooke statement annual report contain certain forward look statement business strategy market potential future financial performance matter word believe expect anticipate project similar expression generally identify forward look statement speak date statement matter discuss forward look statement subject risk uncertainty factor cause actual result differ materially project anticipated imply forward look statement particular information include item business item risk factor item management discussion analysis financial condition result operation contain forward look statement forward look statement expectation belief future result event express expectation belief base current plan expectation abbvie management express good faith believe reasonable basis assurance expectation belief result achieve accomplished factor cause actual result event differ materially anticipate include matter describe item risk factor item management discussion analysis financial condition result operation abbvie undertake obligation update forward look statement include annual report reflect event circumstance date hereof abbvie require applicable security law item b unresolved staff comment item property abbvie corporate office locate north waukegan road north chicago illinois abbvie manufacturing facility follow location united states outside united states abbott park illinois campoverde di aprilia italy barceloneta puerto rico cork ireland jayuya puerto rico ludwigshafen germany north chicago illinois singapore worcester massachusetts sligo ireland wyandotte michigan lease property addition abbvie manufacture facility worldwide abbvie believe facility suitable provide adequate production capacity material encumbrance abbvie own property unite states include puerto rico abbvie distribution center abbvie research development facilities united states locate abbott park illinois north chicago illinois redwood city california south san francisco california sunnyvale california cambridge massachusetts worcester massachusetts outside united states abbvie principal research development facility locate ludwigshafen germany form kitem legal proceeding information pertain legal proceeding provide note legal proceeding contingency consolidated financial statement include item financial statement supplementary datum incorporate reference item safety disclosure applicable executive officer registrant follow table list abbvie executive officer appoint abbvie corporate officer december indicate age position richard gonzalez chairman board chief executive officer carlos alban executive vice president commercial operation william j chase executive vice president chief financial officer henry gosebruch executive vice president chief strategy officer laura j schumacher executive vice president external affairs general counsel corporate secretary michael e severino md executive vice president research development chief scientific officer timothy j richmond senior vice president human resource azita salekigerhardt phd senior vice president operation robert michael vice president controller mr gosebruch appoint corporate officer december dr severino appoint corporate officer june mr michael appoint corporate officer december mr gonzalez chairman chief executive officer abbvie serve abbotts executive vice president pharmaceutical product group july december responsible abbotts worldwide pharmaceutical business include commercial operation research development manufacturing serve president abbott ventures inc abbotts medical technology investment arm mr gonzalez join abbott hold management position briefly retire include abbotts president chief operating officer president chief operating officer abbott medical product group senior vice president president abbotts hospital product division vice president president abbotts health system division divisional vice president general manager abbotts diagnostic operation united states canada mr alban abbvie executive vice president commercial operation serve abbott senior vice president proprietary pharmaceutical product global commercial operation senior vice president international pharmaceutical vice president western europe canada vice president european operations mr alban join abbott mr chase abbvie executive vice president chief financial officer serve abbott vice president license acquisition vice president treasurer divisional vice president controller abbott international mr chase join abbott mr gosebruch abbvie executive vice president chief strategy officer work year merger acquisition group jp morgan securities llc serve manage director cohead north america mr gosebruch join abbvie ms schumacher abbvie executive vice president external affairs general counsel corporate secretary responsible abbvie externallyface function health economic outcome research government affair corporate responsibility brand communication lead abbvie legal function prior abbvie separation abbott ms schumacher serve executive vice president general counsel corporate secretary senior vice president corporate secretary general counsel abbott abbvie ms schumacher lead licensing acquisition venture early stage collaboration abbott ms schumacher responsible office ethic compliance ms schumacher join abbott serve board general dynamic corporation dr severino abbvie executive vice president research development chief scientific officer dr severino serve amgen inc senior vice president global development corporate chief medical officer vice president global development vice president therapeutic area head general medicine inflammation global clinical development join abbvie form kmr richmond abbvie senior vice president human resource serve abbott divisional vice president compensation benefit group vice president talent reward divisional vice president talent acquisition mr richmond join abbott dr salekigerhardt abbvie senior vice president operation serve abbott vice president pharmaceutical manufacturing supply divisional vice president quality assurance global pharmaceutical operation dr salekigerhardt join abbott mr michael vice president controller march abbvie officer serve abbvie vice president treasurer vice president controller commercial operation vice president financial planning analysis abbott mr michael serve division controller nutrition supply chain mr michael join abbott executive officers abbvie elect annually board director officer elect board appoint chairman board officer elect meeting board director hold annual stockholder meeting appoint chairman board board meeting officer hold office successor duly elect appoint qualified officer death resignation removal family relationship executive officer list ii item market registrant common equity relate stockholder matter issuer purchase equity security principal market principal market abbvie common stock new york stock exchange nyse abbvie common stock list chicago stock exchange trade regional electronic exchange market price share high low high low quarter second quarter quarter fourth quarter stockholder stockholder record abbvie common stock january dividend follow table summarize quarterly cash dividend declare year end december date declare payment date dividend share date declare payment date dividend share october abbvie board director declare increase quarterly cash dividend share share payable february stockholders record january time declaration payment dividend abbvie future discretion board director depend factor include abbvie financial condition earning capital requirement operating subsidiary covenant associate certain abbvie debt service obligation legal requirement regulatory constraint industry practice ability access capital market factor deem relevant board director abbvie determine pay dividend future assurance continue pay dividend dividend performance graph follow graph compare cumulative total return abbvie sp index nyse arca pharmaceuticals index graph cover period january day abbvie common stock begin regularway trading nyse december graph assume invest abbvie common stock index january assume reinvestment dividend stock price performance follow graph necessarily indicative future stock price performance form kthis performance graph furnish shall deem file sec subject section security exchange act shall deem incorporate reference abbvie filing securities act amend issuer purchase equity security c total number share unit total purchase maximum number number b average publicly approximate dollar value share price announce share unit unit pay share plan purchase period purchase unit program plan programs october october november november december december total addition abbvie share repurchase open market publicly announce program share include share deem surrender abbvie pay exercise price connection exercise employee stock option october november december average exercise price october november december share include share purchase open market benefit participant abbvie employee stock purchase plan october november december share include share surrender abbvie satisfy minimum tax withholding obligation connection vest exercise stockbase awards february abbvie board director authorize new billion stock repurchase program supersede abbvie previous stock repurchase program new stock repurchase program permit purchase abbvie share time time openmarket private transaction include accelerated share repurchase management discretion program time limit discontinue time form kitem select financial datum select financial information read conjunction financial statement accompany note include item financial statement supplementary datum item management discussion analysis financial condition result operation year end december millions share datum statement earning datum net revenue net earning basic earning share dilute earning share cash dividend declare common share weightedaverage basic share outstanding weightedaverage dilute share outstanding balance sheet datum total asset bc longterm debt lease obligation bcd abbvie declare regular quarterly cash dividend aggregate share common stock addition cash dividend share common stock declare preseparation earning january record reduction additional paidin capital b abbvie acquire pharmacyclic approximately billion include cash consideration billion equity consideration approximately million share abbvie common stock value billion connection acquisition abbvie issue billion aggregate principal unsecured senior note approximately billion finance acquisition approximately billion finance accelerate share repurchase asr program note consolidated financial statement information acquisition pharmacyclic note information senior note note information asr c june abbvie acquire stemcentrx approximately billion include cash consideration billion equity consideration approximately million share abbvie common stock value billion contingent consideration approximately million connection acquisition abbvie issue billion aggregate principal unsecured senior note billion net proceed approximately billion finance acquisition approximately billion finance asr approximately billion repay company outstanding term loan mature november note consolidated financial statement information acquisition stemcentrx note information senior note note information asr include current portion longterm debt lease obligation item management discussion analysis financial condition result operation follow discussion analysis financial condition abbvie inc abbvie company december result operation year period end december commentary read conjunction consolidated financial statement accompany note appear item financial statement supplementary data executive overview company overview abbvie global researchbase biopharmaceutical company form follow separation abbott laboratories abbott abbvie mission use expertise dedicated people unique approach innovation develop market advanced therapy address world complex disease abbvie product focus treat condition chronic autoimmune disease rheumatology gastroenterology dermatology oncology include blood cancer virology include hepatitis c hcv human immunodeficiency virus hiv neurological disorder parkinson disease multiple sclerosis metabolic disease include thyroid disease complication associate cystic fibrosis health condition abbvie pipeline promise new medicine important medical specialty immunology oncology neurology additional target investment cystic fibrosis woman health abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse united states abbvie distribute pharmaceutical product principally independent wholesale distributor sale directly pharmacie patient outside united states sale directly customer distributor depend market serve certain product comarkete copromote company abbvie approximately employee abbvie operate business segmentpharmaceutical product financial result abbvie strategy focus deliver strong financial result advance invest pipeline return value shareholder ensure strong sustainable growth business long term company financial performance include deliver worldwide net revenue billion operating earning billion dilute earning share worldwide net revenue grow constant currency basis drive primarily continue strength humira revenue growth relate imbruvica key product include creon duodopa launch hcv product mavyret increase partially offset decline net revenue hcv product viekira dilute earning share include net charge relate december enactment tax cut job act net charge include billion onetime mandatory repatriation previously untaxe earning foreign subsidiary partially offset aftertax benefit billion remeasurement net defer tax liability relate impact additional aftertax cost impact diluted earning share include follow million relate amortization intangible asset ii million change fair value contingent consideration liability iii million acquire inprocess research development iprd iv litigation reserve charge million v intangible asset impairment charge million vi milestone payment million vii acquisition relate cost million cost partially offset aftertax benefit million tax audit settlement financial result reflect continued add funding support abbvie emerge mid latestage pipeline asset continue investment abbvie growth brand company generate cash flow operation billion abbvie utilize continue enhance pipeline licensing collaboration activity pay cash dividend stockholder billion repurchase approximately million share billion open market october abbvie board director declare quarterly cash dividend share common stock payable february reflect increase approximately previous quarterly dividend share common stock form k strategic objective abbvie mission innovationdriven patientfocuse specialty biopharmaceutical company capable achieve topti financial performance outstanding execution consistent stream innovative new medicine abbvie intend continue advance mission number way include grow revenue diversify revenue stream drive latestage pipeline asset market ensure strong commercial execution new product launch ii continue investment expansion pipeline support opportunitie immunology oncology neurology continue investment key onmarket product iii expand operating margin iv return cash shareholder dividend share repurchase addition abbvie anticipate regulatory submission key data readout key clinical trial month abbvie expect achieve strategic objective humira sale growth drive biologic penetration disease category maintain market leadership effectively manage biosimilar erosion imbruvica revenue growth drive increase market share currently approve indication different disease area strong execution new product launch include mavyret favorable impact pipeline product approve currently regulatory review approval expect product describe great detail section label research development include item abbvie remain committed drive continued expansion operating margin expect achieve objective continue leverage revenue growth reduction humira royalty expense productivity initiative supply chain ongoing efficiency program optimize manufacture commercial infrastructure administrative cost general corporate expense research development research innovation cornerstone abbvie business global biopharmaceutical company abbvie longterm success depend great extent ability continue discover develop innovative pharmaceutical product acquire collaborate compound currently development biotechnology pharmaceutical company abbvie pipeline currently include compound indication clinical development individually collaboration license agreement focus important medical specialty immunology oncology neurology target investment cystic fibrosis woman health program mid latestage development follow section summarize transition significant program phase development phase development development significant phase registration program abbvie expect multiple phase program transition phase program month significant program development immunology upadacitinib june abbvie announce topline result phase selectnext clinical trial evaluate upadacitinib abt company selective jak inhibitor currently latestage development rheumatoid arthritis ra meet primary rank secondary endpoint patient moderate severe ra adequately respond treatment conventional synthetic disease modify antirheumatic drug dmard safety profile upadacitinib consistent previously report phase trial new safety signal detect september abbvie announce topline result phase selectbeyond clinical trial evaluate upadacitinib meet primary rank secondary endpoint patient moderate severe ra adequately respond intolerant treatment biologic dmard safety profile upadacitinib consistent previously report phase trial phase selectnext clinical trial new safety signal detect december abbvie announce topline result phase selectmonotherapy clinical trial evaluate upadacitinib meet primary key secondary endpoint patient moderate severe ra adequately respond treatment methotrexate safety profile upadacitinib consistent previously report phase select clinical trial phase trial new safety signal detect abbvie initiate phase clinical trial evaluate safety efficacy upadacitinib subject moderately severely active crohns disease subject moderately severely active psoriatic arthritis january food drug administration fda grant breakthrough therapy designation upadacitinib adult patient moderate severe atopic dermatitis candidate systemic therapy risankizumab october abbvie announce topline result phase clinical trial evaluate risankizumab investigational interleukin il inhibitor week dosing compare ustekinumab adalimumab meet coprimary rank secondary endpoint treatment patient moderate severe chronic plaque psoriasis safety profile consistent previously report study new safety signal detect study december abbvie announce topline result phase immhance clinical trial evaluate risankizumab week week treatment compare placebo meet primary rank secondary endpoint treatment patient moderate severe plaque psoriasis safety profile consistent previously report phase study new safety signal detect phase program december abbvie initiate phase clinical trial evaluate safety efficacy risankizumab subject moderately severely active crohns disease oncology imbruvica january fda approve imbruvica treatment patient relapsedrefractory marginal zone lymphoma mzl require systemic therapy receive prior anticdbase therapy indication approve accelerate approval base overall response rate orr continued approval contingent verification description clinical benefit confirmatory trial mzl slowgrowe form nonhodgkin lymphoma august fda approve imbruvica treatment adult patient chronic graftversushostdisease cgvhd failure line systemic therapy imbruvica therapy specifically approve adult cgvhd severe potentially life threaten consequence stem cell bone marrow transplant mark sixth disease indication imbruvica medication initial approval approve indication outside cancer december abbvie announce phase innovate clinical trial evaluate imbruvica combination rituximab patient untreated treatmentnave previouslytreate waldenstrms macroglobulinemia wm meet primary endpoint treatment approve newly previouslytreate patient wm venclexta february abbvie initiate phase clinical trial study safety efficacy venetoclax combination azacitidine treatmentnave elderly subject acute myeloid leukemia aml ineligible standard induction therapy highdose chemotherapy abbvie initiate phase clinical trial evaluate venetoclax coadministere low dose cytarabine ldac improve overall survival os versus ldac placebo treatment nave subject aml september abbvie announce topline result phase murano clinical trial evaluate venetoclax tablet combination rituxan rituximab meet primary endpoint prolong progressionfree survival compare bendamustine combination rituxan patient relapsedrefractory chronic lymphocytic leukemia cll december abbvie submit supplemental new drug application snda fda venclexta venetoclax combination rituxan patient relapse refractory cll january abbvie submit snda venclexta monotherapy patient cll relapse refractory bcell receptor inhibitor rovat february abbvie initiate phase clinical trial evaluate efficacy rovalpituzumab tesirine rovat maintenance therapy follow firstline platinum base chemotherapy participant extensive stage small cell lung cancer sclc april abbvie initiate phase clinical trial evaluate rovat compare topotecan subject advance metastatic sclc high level deltalike protein disease progression follow frontline platinumbase chemotherapy abt november abbvie present result intellance trial potential registrationenabling phase study evaluating depatuxizumab mafodotin abt investigational antibody drug conjugate adc target epidermal growth factor receptor egfr combination temozolomide tmz subject recurrent glioblastoma multiforme gbm result intellance study fail meet primary endpoint overall survival abbvie submit regulatory application abt recurrent gbm intellance combination abt tmz perform numerically well lomustine tmz positive trend overall survival observe abbvie file recurrent gbm base datum phase intellance trial evaluate safety efficacy abt combination tmz subject newly diagnose gbm egfr amplification ongoing veliparib april abbvie announce phase study evaluate veliparib investigational oral poly adenosine diphosphateribose polymerase parp inhibitor combination chemotherapy meet primary endpoint study evaluate veliparib combination carboplatin paclitaxel patient squamous nonsmall cell lung cancer nsclc triple negative breast cancer tnbc ongoing phase study include nonsquamous nonsmall cell lung cancer brca breast cancer ovarian cancer virologyliver disease february european committee medicinal product human use chmp grant positive opinion short eightweek treatment viekirax ombitasvirparitaprevirritonavir tablet exviera dasabuvir tablet option previously untreated adult patient genotype b chronic hcv minimal moderate fibrosis july european commission grant marketing authorization maviret glecaprevirpibrentasvir oncedaily ribavirinfree treatment adult hcv infection major genotype gt maviret indicate patient specific treatment challenge include compensate cirrhosis major genotype previously limited treatment option patient severe chronic kidney disease ckd genotype chronic hcv infection august fda approve mavyret glecaprevirpibrentasvir treatment patient chronic hcv genotype infection cirrhosis compensate cirrhosis childpugh mavyret indicate treatment adult patient hcv genotype infection previously treat regiman contain hcv nsa inhibitor nsa protease inhibitor mavyretmaviret week pangenotypic treatment patient cirrhosis new treatment september abbvie submit new drug application fda elagolix investigational orally administer gonadotropin release hormone gnrh antagonist evaluate management endometriosis associate pain october abbvie grant priority review elagolix fda management endometriosis associate pain november abbvie announce detailed result replicate phase extension study evaluate longterm efficacy safety elagolix evaluate management endometriosis associate pain december abbvie announce strategic decision close sonar study phase clinical trial evaluate effect investigational compound atrasentan progression kidney disease patient stage chronic kidney disease type diabete add standard care ongoing monitor renal event observe study reveal considerably few endpoint expect time analysis likely affect ability test sonar study hypothesis abbvie determine justify continue participation patient study decision close sonar study early relate safety concern result operation net revenue comparison present constant currency rate reflect comparative local currency net revenue prior year foreign exchange rate measure provide information change net revenue assume foreign currency exchange rate change prior current period abbvie believe nongaap measure change net revenue constant currency rate conjunction gaap measure change net revenue actual currency rate provide complete understand company operation facilitate analysis company result operation particularly evaluate performance period percent change actual currency rate constant currency rate year end dollar millions united states international net revenue form kthe follow table detail abbvie worldwide net revenue percent change actual currency rate constant currency rate year end december dollar millions humira united states international total imbruvica united states collaboration revenue total hcv united states international total lupron united states international total creon united states synagi international synthroid united states androgel united states kaletra united states international total sevoflurane united states international total duodopa united states international total total net revenue follow discussion analysis abbvie net revenue product present constant currency basis global humira sale increase sale increase drive market growth therapeutic category geographie favorable pricing certain geography sale increase drive approval new indication united states humira sale increase sale increase drive market growth indication favorable pricing sale increase drive market growth indication high market share favorable pricing internationally humira revenue increase drive primarily market growth indication abbvie continue pursue strategy intend differentiate humira compete product add sustainability future growth humira net revenues imbruvica represent product revenues united states collaboration revenue outside united states relate abbvie share imbruvica profit net revenue imbruvica commence follow completion pharmacyclic acquisition global imbruvica sale increase result continue penetration imbruvica firstline treatment patient cll favorable pricing sale increase drive market share gain follow fda ema approval imbruvica firstline treatment patient cll year sale global hcv sale decrease sale decrease result market contraction low market share price erosion viekira factor partially offset launch mavyret certain geography second half net revenue creon increase drive primarily continue market growth high market share creon maintain market leadership pancreatic enzyme market global kaletra net revenue decrease primarily low market share result impact increase competition hiv marketplace abbvie expect net revenue kaletra continue decline net revenue duodopa increase primarily result market penetration geographic expansion gross margin percent change year end december dollar million gross margin percent net revenue gross margin percentage net revenue decrease primarily intangible asset impairment charge million unfavorable impact high intangible asset amortization imbruvica profit sharing arrangement driver partially offset low amortization fair market value stepup acquisitiondate inventory pharmacyclic favorable change product mix operational efficiency gross margin percentage net revenue decrease primarily unfavorable foreign exchange rate unfavorable impact high intangible asset amortization imbruvica profit sharing arrangement high amortization fair market value stepup acquisitiondate inventory pharmacyclic additionally gross margin include intangible asset impairment charge million gross margin include milestone revenue million oncology collaboration partner driver partially offset favorable change product mix operational efficiency form kselling general administrative percent change year end december dollar million sell general administrative percent net revenue sga expense percentage net revenue decrease continue leverage revenue growth partially offset litigation reserve charge million new product launch expense sga expense percentage net revenue decrease continue leverage revenue growth low cost sga expense include cost associate separation abbott million pharmacyclic acquisition integration cost million litigation reserve charge million additionally sga expense reflect marketing support global launch viekira research development acquire inprocess research development percent change year end december dollar million research development percent net revenue acquire inprocess research development research development rd expense increase principally increase funding support company emerge mid latestage pipeline asset impact postacquisition rd expense stemcentrx boehringer ingelheim bi compound increase development milestone million factor partially offset decrease acquisition relate cost million rd expense increase primarily increase funding support company emerge mid latestage pipeline asset increase partially offset follow factor rd expense include million charge relate purchase priority review voucher party ii development milestone decrease million iii result include restructuring charge million acquire inprocess research development iprd expense reflect upfront payment relate collaboration acquire iprd expense include charge million result enter global strategic collaboration alector inc alector develop commercialize medicine treat alzheimer disease neurodegenerative disorder individually significant transaction cash flow acquire iprd expense include charge million result enter exclusive worldwide license agreement cn diagnostic c n develop commercialize antitau antibodie treatment alzheimer disease neurological disorder note consolidated financial statement additional information alector c n agreement nonoperate expense year end december million interest expense interest income interest expense net net foreign exchange loss expense net interest expense increase compare year expense associate issuance billion aggregate principal senior note issue primarily finance acquisition stemcentrx repay outstanding term loan interest expense increase compare year expense associate issuance billion aggregate principal senior note issue primarily finance acquisition pharmacyclic addition incremental expense associate senior note issuance discuss interest expense include debt extinguishment charge million relate redemption senior note mature november increase partially offset absence bridge financing relate cost million incur connection acquisition pharmacyclic interest income continue increase growth company investment security net foreign exchange loss include million historical currency translation loss reclassify accumulated comprehensive income aoci relate liquidation certain foreign entity follow enactment tax reform net foreign exchange loss include loss total million relate devaluation abbvie net monetary asset denominate venezuelan bolivar note consolidated financial statement additional information venezuelan devaluation net foreign exchange loss include loss million complete liquidation company remain foreign currency position relate terminate propose combination shire expense net include charge relate change fair value bi stemcentrx contingent consideration liabilitie million million fair value contingent consideration liability impact passage time multiple input include probability success achieve regulatorycommercial milestone discount rate estimate future sale acquire product development marketbase factor change fair value represent mainly high probability success passage time decline interest rate change fair value represent mainly passage time increase bi contingent consideration liability high probability success fully offset effect rise interest rate change marketbase assumption note consolidated financial statement additional information acquisition stemcentrx bi compound expense net include realize gain availableforsale investment security million expense net include impairment charge total million relate certain company equity investment security income tax expense effective income tax rate effective tax rate period differ statutory tax rate principally benefit foreign operation reflect impact low income tax rate location outside united states tax incentive puerto rico foreign tax jurisdiction business development activity increase effective tax rate prior year principally estimate tax effect enactment tax cut job act act effective tax rate include tax expense billion onetime mandatory repatriation previously untaxe earning foreign subsidiary partially offset billion net tax benefit remeasurement defer taxis relate act foreign tax law change act significantly change corporate tax system act reduce federal corporate tax rate create territorial tax system include new taxis certain foreign sourced earning result effective income tax rate change significantly future period note consolidated financial statement additional information act effective tax rate include additional expense million relate recognition tax effect regulation issue internal revenue service december change determination taxability foreign currency gain loss relate certain foreign operation effective income tax rate include tax benefit million reduction state valuation allowance financial position liquidity capital resource year end december million cash flow operating activity invest activity financing activity operate cash flow increase primarily improved result operation result revenue growth improvement operating earning decrease income tax payment operate cash flow form kdecrease primarily improved result operation result revenue growth improvement operating margin offset income tax payment realize excess tax benefit associate stockbase compensation total million present operate cash flow result adoption new accounting pronouncement prior adoption new accounting pronouncement realize excess benefit million million present cash flow financing activity note consolidated financial statement additional information adoption new accounting pronouncement operating cash flow reflect abbvie voluntary contribution primarily principal domestic define benefit plan million abbvie plan voluntary contribution define benefit plan excess million investing cash flow include capital expenditure million payment acquisition investment million partially offset net sale maturity investment security total million investing cash flow primarily include billion cash consideration pay acquire stemcentrx june million upfront payment acquire certain right bi april net purchase investment security total billion capital expenditure million investing activity primarily include billion cash consideration pay acquire pharmacyclic net cash acquire million investing activity include cash outflow related acquisition investment million include million payment calico million relate exclusive worldwide license agreement cn develop commercialize antitau antibodie treatment alzheimer disease neurological disorder million pay infinity achievement development milestone collaboration agreement cash flow investing activity include capital expenditure million company issue redeem commercial paper balance commercial paper outstanding million december million december abbvie issue additional commercial paper retire commercial paper meet liquidity requirement need november company issue billion aggregate principal unsecured senior euro note company proceed redeem billion aggregate principal senior note mature november connection offer abbvie incur million issuance cost company issue billion aggregate principal senior note approximately billion net proceed repay outstanding term loan mature november approximately billion net proceed finance acquisition stemcentrx approximately billion net proceed finance asr note consolidated financial statement additional information asr transaction connection issuance senior note abbvie incur million issuance cost company issue billion aggregate principal unsecured senior note approximately billion net proceed finance acquisition pharmacyclic billion net proceed finance asr company pay million cost relate billion day bridge term loan credit agreement bridge loan million cost relate issuance senior note amount draw bridge loan terminate result issuance senior note september abbvie enter threeyear billion term loan credit facility day billion term loan credit facility november abbvie draw term facility proceed refinance billion senior note mature cash dividend payment total billion billion billion increase cash dividend payment primarily increase dividend rate october abbvie announce board director declare increase company quarterly cash dividend share share beginning dividend payable february stockholders record january reflect increase approximately previous quarterly rate february abbvie announce board director declare increase company quarterly cash dividend share share beginning dividend payable stockholder record april timing declaration payment dividend abbvie future discretion board director depend factor include abbvie financial condition earning capital requirement operating subsidiary covenant associate certain abbvie debt service obligation legal requirement regulatory constraint industry practice ability access capital market factor deem relevant board director addition asr abbvie exist stock repurchase program company repurchase approximately million share billion approximately million share billion approximately million share billion abbvie cashsettle million december open market purchase january cashsettle million december open market purchase january stock repurchase authorization permit purchase abbvie share time time openmarket private transaction management discretion program time limit discontinue time abbvie remain stock repurchase authorization billion december february abbvie board director authorize new billion stock repurchase program supersede abbvie previous stock repurchase program new stock repurchase program permit purchase abbvie share time time openmarket private transaction include accelerated share repurchase management discretion program time limit discontinue time abbvie pay million contingent consideration bi relate phase enrollment milestone million milestone include finance cash flow million include operate cash flow cash equivalent impact net favorable exchange rate change total million net unfavorable exchange rate change total million million favorable exchange rate change primarily strengthen euro foreign currency translation company eurodenominate asset cash denominate foreign currency unfavorable exchange rate change primarily devaluation abbvie net monetary asset denominate venezuelan bolivar unfavorable exchange rate change principally weakening euro foreign currency translation company eurodenominate asset cash denominate foreign currency prior enactment tax cut job act december significant portion cash equivalent consider reinveste indefinitely foreign subsidiary enactment tax reform significantly change corporate tax system include impose mandatory time transition tax previously untaxe earning foreign subsidiary creation territorial tax system generally allow repatriation future foreign sourced earning incur additional taxis company fully complete analysis calculation foreign earning subject transition tax provisional estimate onetime transition tax billion generally payable annual installment abbvie expect transition tax liability materially affect liquidity capital resource credit risk abbvie monitor economic condition creditworthiness customer government regulation fund domestically abroad abbvie regularly communicate customer status receivable balance include payment plan obtain positive confirmation validity receivables abbvie establishe allowance account receivable probable collect abbvie utilize factoring arrangement mitigate credit risk receivable include arrangement historically significant total outstanding receivables abbvie continue business foreign government certain country include greece portugal italy spain historically experience challenge credit economic condition substantially abbvie trade receivables greece portugal italy spain government health system outstanding governmental receivables country net allowance doubtful account total million december million december company continue business foreign government certain oilexporting country experience deterioration economic condition include saudi arabia russia result delay collection receivables outstanding governmental receivables relate saudi arabia net allowance doubtful account million december million december outstanding governmental receivables relate russia net allowance doubtful account million december million december global economic condition customerspecific factor require company periodically reevaluate collectability receivables company potentially incur credit loss currently abbvie believe economic condition oilexporte country significant impact company liquidity cash flow financial flexibility government funding unavailable country significant adverse change reimbursement practice occur abbvie able collect entire balance outstanding december credit facility access capital credit rating credit facility abbvie currently billion fiveyear revolve credit facility mature october revolve credit facility enable company borrow fund unsecured basis variable interest rate contain covenant december company compliance credit facility covenant commitment fee credit facility insignificant amount outstanding credit facility december form kaccess capital company intend fund shortterm longterm financial obligation mature cash hand future cash flow operation issue additional debt company ability generate cash flow operation issue debt enter financing arrangement acceptable term adversely affect material decline demand company product solvency customer supplier deterioration company key financial ratio credit rating material unfavorable change business condition current time company believe sufficient financial flexibility issue debt enter financing arrangement attract longterm capital acceptable term support company growth objective credit rating change companys credit rating unfavorable change rating adverse impact future financing arrangement affect company ability draw credit facility result acceleration schedule maturities company outstanding debt contractual obligation follow table summarize abbvie estimate contractual obligation december million total year year year year shortterm borrowing longterm debt capital lease obligation include current portion interest longterm debta future minimum noncancelable operating lease commitment purchase obligation otherb longterm liabilitiesc e f total include estimate future interest payment longterm debt capital lease obligation interest payment debt calculate future period forecast interest rate effect end project interest payment include relate effect interest rate swap agreement certain project interest payment differ future base change float interest rate factor event project interest payment pertain obligation agreement outstanding december note consolidated financial statement additional information company debt instrument note additional information interest rate swap agreement outstanding december b include company significant unconditional purchase obligation commitment exceed company project requirement normal course business c amount year include voluntary contribution excess million abbvie plan define benefit plan subsequent december amount exclude pension postemployment benefit relate deferred compensation cash outflow time fund uncertain dependent future movement interest rate investment return change law regulation variable include component longterm liability include restructuring note consolidated financial statement additional information restructuring note additional information pension postemployment benefit plan exclude liability associate company unrecognized tax benefit possible reliably estimate time future cash outflow relate liability note consolidated financial statement additional information unrecognized tax benefit e include billion contingent consideration liability relate acquisition stemcentrx bi compound record fair value consolidate balance sheet potential contingent consideration payment exceed fair value record consolidated balance sheet include table contractual obligation note consolidated financial statement additional information liability f include onetime transition tax liability mandatory deem repatriation previously untaxe earning foreign subsidiary result tax reform enact onetime transition tax generally payable annual installment note consolidated financial statement additional information provisional estimate tax liability abbvie enter rd collaboration arrangement party require future milestone payment party contingent achievement certain development regulatory commercial milestone individually arrangement insignificant annual reporting period milestone multiple product cover arrangement happen reach reporting period aggregate charge expense material result operation period business perspective payment view positive signify product successfully move development generating likely generate future cash flow product sale possible predict reasonable certainty milestone achieve timing achievement result potential payment include table contractual obligation note consolidated financial statement additional information collaboration arrangement form kcritical accounting policy estimate preparation financial statement accordance generally accept accounting principle united states require use estimate assumption affect report amount asset liability report amount revenue expense summary company significant accounting policy include note consolidated financial statement certain policy consider critical significantly impact company financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain actual result vary estimate revenue recognition abbvie recognize revenue persuasive evidence arrangement exist delivery occur sale price fix determinable collectability sale price reasonably assure revenue product sale recognize title risk loss pass customer rebate abbvie provide rebate pharmacy benefit manager state government medicaid programs insurance company administer medicare drug plan wholesaler group purchasing organization government agency private entity rebate chargeback accruals record reduction revenue period relate product sell rebate chargeback total billion billion billion rebate amount typically base volume purchase contractual statutory price vary product payer type rebate factor calculation accrual rebate include identification product subject rebate applicable price term estimate lag time sale payment rebate significant order establish rebate chargeback accruals company use internal external datum estimate level inventory distribution channel rebate claim processing lag time type rebate estimate rebate percentage net price company track sale product customer payer company evaluate inventory datum report wholesaler available prescription volume information product pricing historical experience factor order determine adequacy reserve abbvie regularly monitor reserve record adjustment rebate trend rebate program contract term legislative change significant event indicate change reserve appropriate historically adjustment rebate accrual material net earning follow table analysis large rebate accrual chargeback allowance comprise approximately total consolidated rebate chargeback record reduction revenue remain rebate provision charge gross revenue significant determination operating earning medicaid manage medicare care wholesaler millions rebate rebate chargeback balance december provision payment balance december provision payment balance december provision payment balance december cash discount product return cash discount product return total billion million million record reduction revenue period relate product sell reserve cash discount readily determinable company experience payment history fairly consistent product return reliably estimate base company historical return experience pension postemployment benefit abbvie engage outside actuary assist determination obligation cost pension postemployment benefit plan direct obligation abbvie valuation fund status net periodic benefit cost plan calculate actuarial assumption significant assumption review annually include discount rate expect longterm rate return plan asset health care cost trend rate significant assumption determine calculation disclose note consolidated financial statement discount rate select base current market rate highquality fixedincome investment december year abbvie employs yield curve approach country robust bond market exist yield curve develop highquality bond yield curve approach reflect plan specific cash flow ie duration calculate benefit obligation apply correspond individual spot rate yield curve beginning abbvie reflect plan specific cash flow apply correspond individual spot rate yield curve calculate service cost interest cost portion expense country abbvie review index corporate bond government bond benchmark estimate discount rate abbvie assumed discount rate significant effect amount report define benefit pension postemployment plan december basis point change assume discount rate follow effect abbvie calculation net periodic benefit cost project benefit obligation december basis point million bracket denote reduction increase decrease define benefit plan service interest cost project benefit obligation postemployment plan service interest cost project benefit obligation effective december abbvie elect change method use estimate service interest cost component net periodic benefit cost historically abbvie estimate service interest cost component expense utilize single weightedaverage discount rate derive yield curve measure benefit obligation beginning period late abbvie elect utilize yield curve approach estimation component apply specific spot rate yield curve determination benefit obligation relevant project cash flow abbvie elect change provide precise measurement service interest cost improve correlation project benefit cash flow correspond spot yield curve rate abbvie account change prospectively change accounting estimate inseparable change accounting principle change reduce abbvie net periodic benefit cost approximately million change effect expense affect measurement abbvie total benefit obligation expect longterm rate return base asset allocation historical performance current view expect future return abbvie consider input longterm focus avoid shortterm market influence current longterm rate return plan asset plan support historical performance trust actual target asset allocation abbvie assume expected longterm rate return significant effect amount report define benefit pension plan december calculation net periodic benefit cost percentage point change assume expected longterm rate return plan asset increase decrease net period benefit cost plan million health care cost trend rate select review historical trend current view project future health care cost increase current health care cost trend rate support historical trend experience plan assume health care cost trend rate significant effect amount report health care plan form kdecember calculation net periodic benefit cost percentage point change assume health care cost trend rate follow effect abbvie calculation net periodic benefit cost project benefit obligation december percentage point million bracket denote reduction increase decrease service interest cost project benefit obligation income taxis abbvie account income taxis asset liability method provision federal state foreign income taxis calculate report pretax earning base current tax law defer taxis provide enact tax rate future tax consequence temporary difference difference financial statement carry asset liability respective tax basis tax benefit carryforward valuation allowance establish maintain base currently available information likely portion defer tax asset realize litigation company subject contingency claim legal proceeding investigation product liability intellectual property commercial security matter arise normal course business note consolidated financial statement additional information loss contingency provision record probable loss management good estimate loss good estimate minimum loss contingency probable range record accordingly abbvie initially unable develop good estimate loss minimum zero record information know minimum loss increase result additional loss provision good estimate result additional loss provision occasionally good estimate change low event result expectation favorable outcome previously expect valuation goodwill intangible asset abbvie acquire continue acquire significant intangible asset connection business combination abbvie record fair value transaction involve purchase sale intangible asset occur frequency company pharmaceutical industry valuation usually base discount cash flow analysis incorporate stage completion discount cash flow model require assumption time future net cash flow risk cost capital terminal value market participant factor significantly affect value intangible asset iprd acquire business combination capitalize indefinitelive intangible asset regulatory approval obtain time account definitelived asset amortize estimate useful life discontinuation point intangible asset write iprd acquire transaction business combination expense immediately deem alternative future use payment party subsequent regulatory approval capitalize amortize remain useful life abbvie review recoverability definitelive intangible asset event change circumstance indicate carry value asset recoverable goodwill indefinitelive intangible asset review impairment annually event occur result impairment note consolidated financial statement information annually company test goodwill impairment assess qualitative factor determine likely fair value carrying factor consider assessment include general macroeconomic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance sustained decline company share price company conclude likely fair value report unit carrying quantitative impairment test perform abbvie test indefinitelive intangible asset quantitative impairment test quantitative impairment test company use estimate future cash flow approach require significant judgment respect future volume revenue expense growth rate change work capital use foreign currency exchange rate selection appropriate discount rate asset grouping assumption estimate estimate assumption consistent company business plan market participant view company similar company use alternative estimate assumption increase decrease estimate fair value asset potentially result different impact company result operation actual result differ company estimate contingent consideration fair value measurement contingent consideration liability determine acquisition date base significant unobservable input include discount rate estimate probability time achieve specify development regulatory commercial milestone estimate future sale acquire product development contingent consideration liability revalue fair value subsequent reporting date relate contingency resolve change fair value contingent consideration liability result change number input include discount rate probability achieve milestone time require achieve milestone estimate future sale significant judgment employ determine appropriateness input change input describe material impact company financial position result operation give period december basis point increasedecrease assume discount rate decreasedincrease value contingent consideration liability approximately million additionally december percentage point increasedecrease assume probability success potential indication increaseddecrease value contingent consideration liability approximately million recent accounting pronouncement note consolidated financial statement additional information recent accounting pronouncement form kitem quantitative qualitative disclosure market risk company expose risk earning cash flow equity adversely impact change foreign exchange rate interest rate certain derivative instrument available costeffective basis hedge company underlie economic exposure note consolidated financial statement additional information company financial instrument hedge strategy foreign currency risk abbvie primary net foreign currency exposure euro japanese yen british pound follow table reflect total foreign currency forward exchange contract outstanding december weight fair weight fair average carry average carry contract exchange value contract exchange value millions rate receivablepayable rate receivable receive primarily dollar exchange follow currency euro japanese yen british pound currency na na total company estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract billion december realize appreciation negatively affect earning remain life contract gain loss hedge instrument offset loss gain hedge transaction reduce earning stockholder equity volatility relate foreign exchange appreciation believe reasonably possible nearterm change foreign currency november company issue billion aggregate principal unsecured senior euro note expose foreign currency risk company designate foreign currency denominate note hedge net investment certain foreign subsidiary affiliate result foreign currency translation gain loss relate euro note include accumulate comprehensive income note consolidated financial statement additional information relate senior euro note issuance note consolidated financial statement additional information relate net investment hedge program functional currency company venezuela operation dollar hyperinflationary status venezuelan economy quarter consideration decline economic condition venezuela decline transaction settle official rate abbvie determine net monetary asset denominate venezuelan bolivar vef long expect settle official rate vef dollar divisa complementaria dicom rate quarter abbvie record charge million net foreign exchange loss revalue bolivardenominate net monetary asset dicom rate effect approximately vef dollar december abbvie net monetary asset venezuela insignificant interest rate risk company estimate increase interest rate basis point adversely impact fair value abbvie interest rate swap contract approximately million december realize fair value reduction affect earning remain life contract company estimate increase basis point longterm interest rate decrease fair value longterm debt billion december basis point change believe reasonably possible nearterm change interest rate market price risk abbvie debt security investment portfolio portfolio main exposure market price risk portfolio subject change fair value result interest rate fluctuation market factor abbvie policy mitigate market price risk maintain diversified portfolio limit exposure particular issuer security type placing limit time maturity abbvie investment policy limit investment investment grade credit rating company estimate increase interest rate basis point decrease fair value portfolio approximately million december portfolio liquidate fair value reduction affect income statement period sell nonpublicly trade equity security abbvie hold equity security pharmaceutical biotechnology company trade public stock exchange carry value investment million december million december abbvie monitor investment temporary decline market value charge impairment loss net earning temporary decline estimate value occur impairment charge record insignificant abbvie record impairment charge total million relate certain company investment nonpublicly trade equity security form kitem financial statement supplementary datum consolidate financial statement consolidate statement earning consolidate statement comprehensive income consolidate balance sheet consolidate statement equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm abbvie inc subsidiary consolidate statement earning year end december millions share datum net revenue cost product sell sell general administrative research development acquire inprocess research development total operating cost expense operate earning interest expense net net foreign exchange loss expense net earning income tax expense income tax expense net earning share datum basic earning share dilute earning share cash dividend declare common share weightedaverage basic share outstanding weightedaverage dilute share outstanding accompany note integral consolidated financial statement form kabbvie inc subsidiary consolidate statement comprehensive income year end december million net earning foreign currency translation adjustment net tax expense benefit net investment hedging activity net tax expense benefit pension postemployment benefit net tax expense benefit marketable security activity net tax expense benefit cash flow hedging activity net tax expense benefit comprehensive loss comprehensive income accompany note integral consolidated financial statement abbvie inc subsidiary consolidate balance sheet december millions share datum asset current asset cash equivalent shortterm investment account receivable net inventory prepaid expense total current asset investment property equipment net intangible asset net goodwill asset total asset liabilitie equity current liability shortterm borrowing current portion longterm debt lease obligation account payable accrue liability total current liability longterm debt lease obligation defer income taxis longterm liability commitment contingency stockholder equity common stock par value share authorize share issue december december common stock hold treasury cost share december december additional paidincapital retain earning accumulate comprehensive loss total stockholder equity total liabilities equity accompany note integral consolidated financial statement form kabbvie inc subsidiary consolidate statement equity accumulate common additional share common treasury paidin retain comprehensive year end december million outstanding stock stock capital earning loss total balance december net earning comprehensive loss net tax dividend declare common share issue pharmacyclic stockholder purchase treasury stock stockbase compensation plan balance december net earning comprehensive loss net tax dividend declare common share issue stemcentrx stockholder purchase treasury stock stockbase compensation plan balance december net earning comprehensive loss net tax dividend declare purchase treasury stock stockbase compensation plan balance december accompanying note integral consolidated financial statement abbvie inc subsidiary consolidate statement cash flow year end december million bracket denote cash outflow cash flow operating activity net earning adjustment reconcile net earning net cash operating activity depreciation amortization intangible asset change fair value contingent consideration liability stockbase compensation upfront cost milestone relate collaboration devaluation loss relate venezuela intangible asset impairment impact relate tax reform net change operate asset liability net acquisition account receivable inventory prepaid expense asset account payable liability cash flow operating activity cash flow invest activity acquisition business net cash acquire acquisition investment acquisition property equipment purchase investment security sale maturity investment security cash flow invest activity cash flow financing activity net change shortterm borrowing proceed issuance longterm debt repayment longterm debt lease obligation debt issuance cost dividend pay purchase treasury stock proceed exercise stock option payment contingent consideration liability net cash flow financing activity effect exchange rate change cash equivalent net change cash equivalent cash equivalent begin year cash equivalent end year supplemental information interest pay net portion capitalize income taxis pay supplemental schedule noncash investing financing activity issuance common share associate acquisition business accompany note integral consolidated financial statement form kabbvie inc subsidiary note consolidated financial statement note background basis presentation background principal business abbvie inc abbvie company discovery development manufacture sale broad line pharmaceutical product abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse substantially abbvie net revenues united states wholesaler outside united states product sell primarily customer distributor depend market serve abbvie incorporate delaware april january abbvie independent publiclytraded company result distribution abbott laboratories abbott outstanding common stock abbvie abbott shareholder abbvie incur separationrelate expense million principally classify sell general administrative expense sga consolidated statement earning basis historical presentation certain portion abbvie operation legal transfer abbvie asset net liability occur separation abbvie january time require transfer marketing authorization satisfy regulatory requirement certain country term separation agreement abbott abbvie responsible business activity conduct abbott behalf subject risk entitle benefit generate operation asset result related asset liability result operation report abbvie consolidate financial statement operation transfer abbvie december net revenue relate operation insignificant million note summary significant accounting policy use estimate consolidated financial statement prepare accordance generally accept accounting principle gaap necessarily include amount base estimate assumption management actual result differ amount significant estimate include amount rebate pension postemployment benefit income taxis litigation valuation goodwill intangible asset contingent consideration liability financial instrument inventory account receivable exposure basis consolidation consolidated financial statement include account abbvie subsidiary control interest maintain control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity abbvie determine primary beneficiary investment company abbvie significant influence control interest account equity method abbvie share earning loss report expense net consolidated statement earning investment generally account cost method intercompany balance transaction eliminate certain reclassification conform prior period consolidated financial statement current period presentation revenue recognition abbvie recognize revenue persuasive evidence arrangement exist delivery occur sale price fix determinable collectability sale price reasonably assure revenue product sale recognize title risk loss pass customer provision discount rebate sale incentive customer return adjustment provide period relate revenue record rebate amount typically base volume purchase contractual statutory price vary product payer type rebate factor calculation accrual include identification product subject rebate applicable price term estimate lag time sale payment rebate significant sale incentive customer insignificant historical datum readily available reliable estimating reduction gross revenue revenue launch new product improve version exist product shipment excess customer normal requirement record condition note meet situation management record return reserve revenue necessary sale product right marketable product record revenue disposition right research development expense internal research development rd cost expense incur clinical trial cost incur party expense contract work perform contingent milestone payment party research development collaboration precommercialization milestone milestone payment obligation expense milestone result achieve payment party subsequent regulatory approval capitalize intangible asset amortize cost product sell remain useful life relate product collaboration arrangement company enter collaborative agreement party develop commercialize drug candidate collaborative activity include joint research development commercialization new product abbvie generally receive certain licensing right arrangement collaboration require upfront payment include additional milestone research development cost share royalty profit share payment contingent occurrence certain future event link success asset development commercialization upfront payment associate collaborative arrangement development stage expense acquire inprocess research development iprd expense consolidate statement earning subsequent payment partner achievement milestone development stage expense rd expense consolidated statement earning milestone achieve milestone payment partner subsequent regulatory approval capitalize intangible asset amortize cost product sell estimated useful life relate asset royalty expense cost product sell consolidated statement earning incur advertising cost associate advertising expense incur include sga consolidated statement earning advertising expense million million million pension postemployment benefit abbvie record annual expense relate define benefit pension postemployment benefit plan base calculation utilize actuarial assumption include discount rate rate return asset compensation increase turnover rate health care cost trend rate abbvie review actuarial assumption annual basis make modification assumption base current rate trend actuarial gain loss defer accumulate comprehensive loss aoci net tax amortize remain service attribution period employee corridor method difference expect longterm return plan asset actual annual return amortize net periodic benefit cost fiveyear period income taxis income taxis account asset liability method provision federal state foreign income taxis calculate report pretax earning base current tax law defer taxis provide enact tax rate future tax consequence temporary difference difference financial statement carry amount asset liability respective tax basis tax benefit carryforward valuation allowance establish maintain base currently available information likely portion defer tax asset realize cash equivalent cash equivalent include money market fund time deposit original maturity month investment investment consist primarily time deposit marketable debt security heldtomaturity debt security equity security investment marketable security classify availableforsale record fair value unrealize holding gain loss net tax include aoci consolidated balance sheet investment equity security trade public stock exchange heldtomaturity debt security record cost form kabbvie periodically assess investment security otherthantemporary impairment loss evaluation base number factor include length time extent fair value cost basis adverse condition relate specifically security include change credit rating security intent sell abbvie likely require sell security recovery amortize cost basis abbvie consider industry factor general market trend abbvie determine temporary decline occur cost basis investment write charge expense income net consolidated statement earning availableforsale investment unrealized loss reclassify aoci expense income net consolidated statement earning realize gain loss sale investment compute firstin firstout method adjust otherthantemporary decline fair value record net earning account receivable account receivable state net realizable value allowance doubtful account reflect good estimate probable loss inherent receivables portfolio determine basis historical experience specific allowance know troubled account currently available information account receivable write reasonable mean collect include litigation appropriate exhausted allowance doubtful account million december million december inventory inventory value low cost firstin firstout basis market cost include material conversion cost inventory consist follow december million finish good workinprocess raw material inventory property equipment december million land building equipment construction progress property equipment gross accumulate depreciation property equipment net depreciation property equipment record straightline basis estimate useful life asset estimate useful life building range year building include leasehold improvement amortize life relate facility lease include renewal period appropriate asset whichever shorter estimate useful life equipment range year equipment include certain computer software software development cost incur connection develop obtain software internal use amortize year depreciation expense million million million asset relate capital lease insignificant december litigation contingency loss contingency provision record probable liability incur liability reasonably estimate base exist information good estimate minimum loss contingency probable range record legal fee expense incur abbvie accrue product liability claim undiscounte basis liability evaluate quarterly adjust necessary additional information available receivables insurance recovery product liability claim record asset undiscounte basis probable recovery realize business combination abbvie utilize acquisition method accounting business combination method require thing result operation acquire company include abbvie result operation begin respective acquisition date asset acquire liability assume recognize fair value acquisition date excess fair value consideration transfer fair value net asset acquire recognize goodwill contingent consideration liability recognize estimate fair value acquisition date subsequent change fair value contingent consideration liability recognize expense income net consolidated statement earning fair value asset acquire liability assume certain case subject revision base final determination fair value period time generally exceed month acquisition date legal cost diligence cost business valuation cost business acquisition cost expense incur goodwill intangible asset intangible asset acquire business combination record fair value discount cash flow model discount cash flow model require assumption time future net cash flow risk cost capital terminal value market participant definitelive intangible amortize estimate useful life estimate pattern economic benefit abbvie review recoverability definitelive intangible asset event change circumstance indicate carry value asset recoverable abbvie compare project undiscounted cash flow generate asset carrying value undiscounte cash flow intangible asset carrying value intangible asset write fair value cash flow identify individual asset review apply low level cash flow largely independent cash flow asset liability goodwill indefinitelive asset amortize subject impairment review annually frequently indicator impairment exist impairment goodwill occur carry reporting unit exceed fair value report unit impairment indefinitelive intangible asset occur fair value intangible asset carrying value company test goodwill impairment assess qualitative factor determine likely fair value carrying company conclude likely fair value report unit carrying quantitative impairment test perform abbvie test indefinitelive intangible asset quantitative impairment test quantitative impairment test company use estimate future cash flow approach require significant judgment respect future volume revenue expense growth rate change work capital use future foreign currency exchange rate selection appropriate discount rate asset grouping assumption estimate estimate assumption consistent company business plan market participant view company similar company use alternative estimate assumption increase decrease estimate fair value asset potentially result different impact company result operation actual result differ company estimate acquire inprocess research development asset acquisition initial cost right iprd project acquire expensed iprd consolidated statement earning project alternative future use cost include initial payment incur prior regulatory approval connection research development collaboration agreement provide right develop manufacture market andor sell pharmaceutical product business combination fair value iprd project acquire capitalize account indefinitelive intangible asset underlie project receive regulatory approval point intangible asset account definitelive intangible asset discontinuation point intangible asset write rd cost incur acquisition expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar periodend exchange rate dollar effect arise translate net asset subsidiary change rate recognize comprehensive loss income oci consolidate statement comprehensive income net asset subsidiary highly inflationary economy remeasure functional currency report currency remeasurement recognize net foreign exchange loss consolidate statement earning form kderivative derivative instrument recognize asset liabilitie fair value consolidate balance sheet classify current longterm base scheduled maturity instrument derivative formally designate hedge company assess inception quarterly hedge derivative highly effective offset change fair value cash flow hedge item change fair value derivative designate fair value hedge hedge item attributable hedge risk recognize earning immediately effective portion change fair value derivative designate cash flow hedge report aoci subsequently recognize earning consistent underlying hedged item determine derivative long highly effective hedge company discontinue hedge accounting prospectively hedge forecast transaction probable occur gain loss reclassify aoci earning derivative designate hedge adjust fair value current earning company use derivative instrument foreign currency denominate debt hedge net investment certain foreign subsidiary affiliate realize unrealized gain loss hedge include aoci derivative cash flow exception net investment hedge principally classified operating section consolidate statement cash flow consistent underlying hedged item cash flow related net investment hedge classify investing section consolidate statement cash flow recent accounting pronouncement recently adopt accounting pronouncement january financial accounting standard board fasb issue accounting standard update asu business combination topic clarify definition business standard provide clarify guidance assist evaluation transaction treat business combination asset acquisition abbvie elect early adopt change prospectively quarter march fasb issue asu compensationstock compensation topic improvement employee sharebase payment accounting abbvie adopt standard quarter result excess tax benefit associate stockbased award recognize statement earning award vest settle stockholder equity addition excess tax benefit statement cash flow classified operating activity finance activity abbvie adopt change prospectively accordingly company recognize excess tax benefit income tax expense million classify cash flow operating activity recent accounting pronouncement adopt fasb issue asu summary amendment create revenue contract customer topic asset defer costscontract customer subtopic amendment standard supersede current revenue recognition requirement core principle new guidance entity recognize revenue depict transfer promise good service customer reflect consideration entity expect entitled exchange good service abbvie apply amendment follow method retrospectively prior reporting period present ii modify retrospectively cumulative effect initially apply amendment recognize date initial application abbvie adopt standard effective quarter apply amendment modify retrospective method company complete assessment new standard december abbvie expect significant change amount time revenue recognition product sale primary revenue stream adoption new standard require cumulativeeffect adjustment retain earning january approximately million net tax primarily related certain defer license revenue originally expect recognize early january fasb issue asu financial instrumentsoverall subtopic recognition measurement financial asset financial liability standard require target change include equity investment account equity method accounting result consolidation investee measure fair value change fair value recognize net earning provision impact accounting abbvie investment debt security new guidance change certain disclosure requirement aspect current gaap amendment apply cumulativeeffect adjustment balance sheet begin fiscal year adoption standard effective abbvie start quarter base historical trend abbvie believe adoption material impact consolidate financial statement february fasb issue asu lease topic standard outline comprehensive lease accounting model supersede current lease guidance require lessee recognize lease liability correspond rightofuse asset lease lease term great month guidance change definition lease expand disclosure requirement lease arrangement new standard adopt modify retrospective approach effective abbvie start quarter early adoption permit abbvie adopt standard effective quarter currently assess impact adopt guidance consolidated financial statement june fasb issue asu financial instrument credit loss topic standard change credit loss measure financial asset certain instrument trade receivable heldtomaturity debt security loan financial instrument standard require use new forwardlooking expect credit loss model generally result early recognition allowance loss availableforsale debt security unrealize loss standard require allowance record instead reduce amortize cost investment additionally standard require new disclosure effective abbvie start quarter early adoption begin quarter permit certain exception adjustment apply modifiedretrospective approach reflect adjustment cumulativeeffect impact retain earning begin fiscal year adoption abbvie currently assess impact timing adopt guidance consolidated financial statement october fasb issue asu income taxis topic new standard require entity recognize income tax consequence intercompany transfer asset inventory transfer occur current gaap income tax consequence intercompany asset transfer defer asset sell party recover use standard effective abbvie start quarter adjustment update apply modify retrospective basis cumulativeeffect adjustment directly retain earning adjustment reflect begin fiscal year adoption company complete assessment new standard december adoption require cumulativeeffect adjustment retain earning january approximately billion relate prepaid income tax asset affect standard billion include prepay expense consolidate balance sheet december march fasb issue asu compensation retirement benefit topic improve presentation net periodic pension cost net periodic postretirement benefit cost standard require employer continue report service cost component net periodic benefit cost income statement line item item employee compensation cost arise service render period component net periodic benefit cost require present separately outside income operation eligible capitalization standard effective abbvie start quarter adoption company apply income statement classification provision standard retrospectively reclassify income million operating earning nonoperate income year end december additionally company preliminarily expect record approximately million nonoperating income record operating earning previous guidance august fasb issue asu derivative hedge topic target improvement accounting hedging activity standard simplifie application hedge accounting closely align accounting entitys risk management activity abbvie early adopt standard effective quarter believe adoption material impact consolidate financial statement form knote supplemental financial information interest expense net year end december million interest expense interest income interest expense net account payable accrue liability december million sale rebate account payable dividend payable salary wage commission royalty license arrangement account payable accrue liability longterm liability december millions contingent consideration liability pension postemployment benefit liability unrecognize tax benefit income taxis payable longterm liability note earning share abbvie grant certain restrict stock award rsas restrict stock unit rsus consider participate security presence participate security abbvie calculate earning share ep dilutive treasury stock twoclass method period present twoclass method dilutive follow table summarize impact twoclass method year end december millions share information basic eps net earning earning allocate participate security earning available common shareholder weightedaverage basic share outstanding basic earning share dilute eps net earning earning allocate participate security earning available common shareholder weightedaverage share common stock outstanding effect dilutive security weightedaverage dilute share outstanding diluted earning share describe note abbvie enter execute accelerated share repurchase agreement asr party financial institution purpose calculate eps abbvie reflected asr repurchase abbvie common stock relevant period certain share issuable stockbase compensation plan exclude computation eps effect antidilutive number common share exclude insignificant period present note license acquisition arrangement acquisition stemcentrx june abbvie acquire outstanding equity interest stemcentrx privatelyheld biotechnology company transaction expand abbvie oncology pipeline add latestage asset rovalpituzumab tesirine rovat additional earlystage clinical compound solid tumor indication significant portfolio preclinical asset rovat currently registrational trial small cell lung cancer acquisition stemcentrx account business combination acquisition method accounting aggregate upfront consideration acquisition stemcentrx consist approximately million share abbvie common stock issue common stock hold treasury cash abbvie certain contingent payment achievement define development regulatory milestone acquisition date maximum aggregate payable development regulatory milestone billion acquisitiondate fair value milestone million estimate combination probabilityweighte discount cash flow model monte carlo simulation model estimate determine base significant input observable market refer level input describe detail note follow table summarize total consideration million cash fair value abbvie common stock contingent consideration total consideration form kthe follow table summarize fair value asset acquire liability assume june acquisition date million asset acquire liability assume account receivable prepay expense property equipment intangible asset indefinitelive research development account payable accrue liability defer income taxis longterm liability total identifiable net asset goodwill total asset acquire liability assume intangible asset relate iprd rovat additional earlystage clinical compound solid tumor indication additional pre clinical compound estimate fair value acquire iprd determine multiperiod excess earning model income approach valuation technique provide estimate fair value asset base market participant expectation cash flow asset generate remain useful life significant assumption inherent development asset valuation include estimate annual cash flow asset product include net revenue cost sale rd cost sell marketing cost work capitalcontributory asset charge appropriate discount rate select order measure risk inherent future cash flow stream assessment asset life cycle regulatory approval probability commercial success risk competitive landscape factor goodwill recognize represent expect synergy include ability leverage respective strength business ii expand combined company product portfolio iii accelerate abbvie clinical commercial presence oncology iv establish strong leadership position oncology goodwill impact establishment defer tax liability acquire identifiable intangible asset tax basis goodwill deductible tax purpose follow acquisition date operating result stemcentrx include company financial statement abbvie consolidated statement earning year end december include net revenue operate loss million associate stemcentrx operation operating loss include million postacquisition stockbase compensation expense stemcentrx option exclude interest expense certain acquisition cost pro forma financial information follow table present unaudited pro forma combine result operation abbvie stemcentrx year end december acquisition stemcentrx occur january year end december millions share information net revenue net earning basic earning share dilute earning share unaudite pro forma financial information prepare acquisition method accounting base historical financial information abbvie stemcentrx order reflect occurrence acquisition january require unaudited pro forma financial information include adjustment reflect additional interest expense associate issuance debt finance acquisition reclassification acquisition integration financingrelate cost incur year end december year end december unaudited pro forma financial information necessarily indicative consolidated result operation acquisition complete january addition unaudite pro forma financial information projection future result operation combine company reflect expect realization cost saving synergy associated acquisition acquisition bi bi boehringer ingelheim april abbvie acquire right risankizumab bi antiil monoclonal biologic antibody phase development psoriasis boehringer ingelheim bi pursuant global collaboration agreement abbvie evaluate potential biologic therapy indication include crohns disease psoriatic arthritis asthma addition risankizumab abbvie gain right anticd antibody bi currently phase development bi retain responsibility development bi abbvie elect advance program completion certain clinical achievement acquire asset include patent data knowhow thirdparty agreement regulatory filing manufacturing technology relate bi bi company conclude acquire asset meet definition business account transaction business combination acquisition method accounting term agreement abbvie upfront payment million additionally million payment bi pursuant contractual obligation reimburse bi certain development cost incur prior acquisition date initially defer abbvie certain contingent payment achievement define development regulatory commercial milestone royalty payment base net revenue license product acquisition date maximum aggregate payable development regulatory milestone approximately billion acquisitiondate fair value milestone million acquisitiondate fair value contingent royalty payment billion potential contingent consideration payment estimate apply probabilityweighte expect payment model contingent milestone payment monte carlo simulation model contingent royalty payment discount present value fair value measurement base level input follow table summarize total consideration million cash defer consideration payable contingent consideration total consideration follow table summarize fair value asset acquire april acquisition date million asset acquire identifiable intangible asset indefinitelive research development goodwill total asset acquire estimate fair value acquire iprd determine multiperiod excess earning model income approach goodwill recognize represent expect synergy include expansion company immunology product portfolio pro forma result operation acquisition present acquisition insignificant abbvie consolidated result operation acquisition pharmacyclic abbvie acquire pharmacyclic biopharmaceutical company develop commercialize novel therapy people impact cancer pharmacyclic market imbruvica ibrutinib bruton tyrosine kinase btk inhibitor target bcell malignancy form kthe acquisition pharmacyclic account business combination acquisition method accounting total consideration acquisition pharmacyclic consist cash approximately million share abbvie common stock summarize follow million cash fair value abbvie common stock total consideration follow table summarize fair value asset acquire liability assume acquisition date million asset acquire liability assume cash equivalent shortterm investment account receivable inventory asset intangible asset definitelive develop product right definitelive license agreement indefinitelive research development account payable accrue liability defer income taxis longterm liability total identifiable net asset goodwill total asset acquire liability assume amortization fair market value stepup acquire inventory include cost product sell rd consolidate statement earning relate amortization million million million intangible asset relate imbruvica develop product right iprd united states additional imbruvica indication contractual right imbruvica profit loss outside united states result collaboration agreement janssen biotech inc affiliates janssen janssen pharmaceutical companies johnson johnson note additional information collaboration janssen acquire definitelive intangible asset amortize weightedaverage estimate useful life year estimate pattern economic benefit estimate fair value iprd identifiable intangible asset determine income approach goodwill recognize acquisition pharmacyclic include expect synergy include ability leverage respective strength business expand combine company product portfolio acceleration clinical commercial presence oncology establishment strong leadership position hematological oncology goodwill deductible tax purpose acquisition date december abbvie consolidated statement earning include net revenue million operating loss million associate pharmacyclic operation operating loss include million acquisitionrelate compensation expense million inventory stepup intangible asset amortization million transaction integration cost cost million record sga expense million rd expense million cost product sell consolidated statement earning pro forma financial information follow table present unaudited pro forma combine result operation abbvie pharmacyclic acquisition pharmacyclic occur january year end december millions share information net revenue net earning basic earning share dilute earning share unaudite pro forma financial information prepare acquisition method accounting base historical financial information abbvie pharmacyclic order reflect occurrence acquisition january require unaudited pro forma financial information include adjustment reflect incremental amortization expense incur base fair value identifiable intangible asset acquire incremental cost product sell relate fair value adjustment associate acquisitiondate inventory additional interest expense associate issuance debt finance acquisition reclassification acquisition integration financingrelate cost incur year end december year end december unaudited pro forma financial information necessarily indicative consolidated result operation acquisition complete january addition unaudite pro forma financial information projection future result operation combine company reflect expect realization cost saving synergy associated acquisition licensing acquisition activity exclude acquisition cash outflow related acquisition investment total million million million abbvie record iprd charge million million million significant arrangement impact require contingent milestone payment summarize alector inc october abbvie enter global strategic collaboration alector inc alector develop commercialize medicine treat alzheimer disease neurodegenerative disorder abbvie alector agree research portfolio antibody target abbvie option global development commercial right target term arrangement include initial upfront payment million expensed iprd fourth quarter alector conduct exploratory research drug discovery development lead program conclusion proof concept study option exercise abbvie lead development commercialization activity additional payment alector million achievement certain development regulatory milestone alector abbvie cofund development commercialization share global profit equally cn diagnostic march abbvie enter exclusive worldwide license agreement cn diagnostic cn develop commercialize antitau antibodie treatment alzheimer disease neurological disorder agreement abbvie initial upfront payment million expense iprd abbvie additional payment million record rd expense achievement development milestone license agreement achievement certain development regulatory commercial milestone abbvie additional payment million royalty net revenue arrangement addition significant arrangement describe abbvie enter arrangement result charge iprd million million million connection individually insignificant early stage arrangement enter abbvie additional payment billion achievement certain development regulatory commercial milestone form kother activity priority review voucher prv august abbvie enter agreement purchase rare pediatric disease prv party prv entitle abbvie receive fda priority review single new drug application biologic license application reduce target review time lead expedite approval exchange prv abbvie payment million record rd expense consolidated statement earning operating cash outflow consolidate statement cash flow abbvie intend use prv exist rd project note collaboration janssen biotech inc december pharmacyclic enter worldwide collaboration license agreement janssen joint development commercialization imbruvica novel orally active selective covalent inhibitor btk certain compound structurally relate imbruvica oncology indication exclude immune inflammatory mediate disease condition psychiatric psychological disease conditions united states outside united states collaboration provide janssen exclusive license commercialize imbruvica outside united states coexclusively abbvie united states party responsible development manufacturing marketing product generate result collaboration collaboration set duration specific expiration date provide potential future development regulatory approval milestone payment million abbvie collaboration include cost sharing arrangement associate collaboration activity certain case janssen responsible approximately collaboration development cost abbvie responsible remain collaboration development cost united states party coexclusive right commercialize product abbvie principal end customer product sale abbvie janssen share pretax profit loss equally commercialization product sale imbruvica include abbvie net revenue janssen share profit include abbvie cost product sell cost incur collaboration report respective expense line item net janssen share outside united states janssen responsible exclusive right commercialize imbruvica abbvie janssen share pretax profit loss equally commercialization product abbvie share profit include abbvie net revenue cost incur collaboration report respective expense line item net janssen share follow table show profit cost sharing relationship janssen abbvie year end december millions united states janssen share profit include cost product sell international abbvie share profit include net revenue global abbvie share cost include respective line item note goodwill intangible asset goodwill follow table summarize change carry goodwill million balance december addition note foreign currency translation balance december foreign currency translation balance december late impairment assessment goodwill complete quarter december accumulate goodwill impairment loss future impairment test goodwill perform annually quarter early impairment indicator exist intangible asset net follow table summarize intangible asset gross net gross net carry accumulate carrying carry accumulate carry december million amortization amortization definitelive intangible asset develop product right license agreement total definitelive intangible asset indefinitelive research development total intangible asset net definitelive intangible asset amortize estimate useful life range year average year develop product right year license agreement amortization expense billion million million include cost product sell consolidated statement earning anticipate annual amortization expense definitelive intangible asset record december follow billion anticipate annual amortization expense impairment charge million record relate zinbryta reduce gross carrying net carrying underlie intangible asset lower expect future cash flow product impairment charge million record related certain develop product right united states decline market product intangible asset impairment charge record impairment charge base discount cash flow analysis include cost product sell consolidated statement earning indefinitelive intangible asset represent acquire iprd associate product receive regulatory approval indefinitelive intangible asset december relate acquisition stemcentrx bi compound note additional information late impairment assessment indefinitelive intangible asset complete quarter impairment charge record future impairment test indefinitelive intangible asset perform annually quarter early impairment indicator exist form knote restructuring plan abbvie continuously evaluate operation identify opportunity optimize manufacturing rd operation commercial infrastructure administrative cost respond change business environment example conjunction loss expect loss exclusivity certain product result abbvie management periodically approve individual restructuring plan achieve objective plan individually significant restructuring charge record million million million primarily relate employee severance contractual obligation charge record cost product sell rd expense sga expense consolidate statement earning base classification affect employee operation follow summarize cash activity restructuring reserve millions accrue balance december restructuring charge payment adjustment accrue balance december restructuring charge payment adjustment accrue balance december restructuring charge payment adjustment accrue balance december note debt credit facility commitment contingency follow table summarize longterm debt effective effective interest rate interest rate december dollar million senior note issue note note note senior note issue note note note note note note senior note issue note note note note note senior euro note issue note principal note principal note principal term loan facility float rate note fair value hedge unamortized bond discount unamortize deferred financing cost total longterm debt lease obligation current portion noncurrent portion exclude effect related interest rate swap november company issue billion aggregate principal unsecured senior euro note senior note rank equally unsecured unsubordinated indebtedness company abbvie redeem senior note prior maturity redemption price equal principal senior note redeem plus makewhole premium abbvie redeem senior note par month prior maturity connection offer debt issuance cost total million debt discount incur total million amortize respective term senior note interest expense net consolidated statement earning company proceed redeem billion aggregate principal senior note mature november result redemption company incur charge million million tax relate makewhole premium writeoff unamortized debt issuance cost expense charge record interest expense net consolidated statement earning form kin company issue billion aggregate principal unsecured senior note senior note rank equally unsecured unsubordinated indebtedness company abbvie redeem senior note prior maturity redemption price equal principal senior note redeem plus makewhole premium abbvie redeem senior note par month prior maturity connection offer debt issuance cost total million debt discount incur total million amortize respective term senior note interest expense net consolidated statement earning billion net proceed billion repay company outstanding term loan mature november approximately billion finance acquisition stemcentrx approximately billion finance asr party financial institution note additional information relate acquisition stemcentrx note additional information relate asr september abbvie enter billion threeyear term loan credit agreement billion day term loan credit agreement collectively term loan facility november abbvie draw term loan facility proceed refinance billion senior note mature november connection unsecured senior note issuance abbvie repay day term loan credit agreement borrowing term loan facility bear interest variable rate adjust base abbvie public debt rating company issue billion aggregate principal unsecured senior note senior note rank equally unsecured unsubordinated indebtedness company abbvie redeem senior note prior maturity redemption price equal principal senior note redeem plus makewhole premium note abbvie redeem senior note par month prior maturity debt issuance cost incur connection offering total million amortize respective term senior note interest expense net consolidated statement earning approximately billion net proceed finance acquisition pharmacyclic approximately billion net proceed finance asr party financial institution note additional information relate acquisition pharmacyclic note additional information relate asr march abbvie enter billion bridge loan support plan acquisition pharmacyclic amount draw bridge loan terminate result company senior note issuance interest expense net include million cost relate bridge loan abbvie outstanding billion aggregate principal unsecured senior note issue abbvie redeem senior note series time senior note series time time redemption price equal principal senior note redeem plus makewhole premium december company compliance senior note covenant term loan covenant shortterm borrowing shortterm borrowing include commercial paper borrowing million december million december weightedaverage interest rate commercial paper borrowing october abbvie enter billion fiveyear revolve credit facility mature october revolve credit facility enable company borrow fund unsecured basis variable interest rate contain covenant december company compliance credit facility covenant commitment fee abbvie revolve credit facility insignificant amount outstanding credit facility december december maturities longterm debt capital lease obligation follow table summarize abbvie future minimum lease payment noncancelable operating lease debt maturity future minimum lease payment capital lease obligation december operate debt maturity year end december million lease capital lease total obligation commitment fair value hedge unamortized bond discount defer financing cost total longterm debt lease obligation lease expense million million million abbvie operating lease generally include renewal option provide company pay taxis maintenance insurance operating cost lease property december annual future minimum lease payment capital lease obligation insignificant contingency guarantee connection separation abbvie indemnify abbott liability result operation abbvie business income tax liability respect period prior distribution date liability agree abbvie abbott abbvie material exposure offbalance sheet arrangement specialpurpose entity ordinary course business abbvie periodically enter thirdparty agreement assignment product right result abbvie secondarily liable obligation abbvie previously primarily liable base past experience likelihood payment agreement remote note financial instrument fair value measure risk management policy company expose foreign currency exchange rate interest rate risk relate business operation abbvie hedge policy attempt manage risk acceptable level base company judgment appropriate tradeoff risk opportunity cost company use derivative nonderivative instrument reduce exposure foreign currency exchange rate abbvie periodically enter interest rate swap company agree exchange specify interval difference fix float interest amount calculate reference agree notional derivative instrument trading purpose manage exposure change interest rate investment security company outstanding derivative instrument contain credit risk relate contingent feature collateral generally require financial instrument abbvie foreign subsidiary enter foreign currency forward exchange contract manage exposure change foreign exchange rate anticipate intercompany transaction denominate currency functional currency local entity contract notional amount total billion december billion december designate cash flow hedge record fair value duration forward exchange contract generally eighteen month accumulate gain loss december reclassify aoci include cost product sell time product sell generally exceed month date settlement company enter foreign currency forward exchange contract manage exposure foreign currency denominate trade payable receivables intercompany loan contract designate hedge record fair value result gain loss reflect net foreign exchange loss consolidated statement form kearning generally offset loss gain foreign currency exposure manage contract notional amount total billion december billion december company use foreign currency forward exchange contract foreign currency denominate debt hedge net investment certain foreign subsidiary affiliate fourth quarter company issue billion aggregate principal senior euro note designate principal amount foreign denominate debt net investment hedge concurrently company settle foreign currency forward exchange contract aggregate notional amount billion designate net investment hedge abbvie party interest rate hedge contract designate fair value hedge notional amount total billion december billion december effect hedge contract change fixedrate interest obligation float rate portion debt abbvie record contract fair value adjust carry fixedrate debt offset follow table summarize amount location abbvie derivative instrument consolidate balance sheet fair value fair value derivative asset position derivative liability position december million balance sheet caption balance sheet caption foreign currency forward exchange contract account payable designate cash flow hedge prepaid expense accrue liability account payable designate hedge prepaid expense accrue liability interest rate swap designate fair value account payable hedge prepaid expense accrue liability interest rate swap designate fair value hedge asset longterm liability total derivative certain derivative subject netting arrangement company counterpartie company offset derivative asset liability consolidated balance sheet follow table present pretax amount gain loss derivative instrument recognize comprehensive loss cash flow net investment cash flow net investment cash flow net investment year end december million hedge hedges total hedge hedge total hedge hedge total foreign currency forward exchange contract hedge ineffectiveness insignificant period present assume market rate remain constant contract maturity company expect transfer pretax unrealized loss million cost product sell foreign currency cash flow hedge month company recognize comprehensive loss pretax loss million pretax gain million relate non derivative foreign currency denominate debt designate net investment hedge follow table summarize pretax amount location derivative instrument net gain loss recognize consolidated statement earning include effective portion net gain loss reclassify aoci net earning note net gain loss reclassify aoci year end december million statement earning caption foreign currency forward exchange contract designate cash flow hedge cost product sell designate hedge net foreign exchange loss nondesignate treasury rate lock agreement expense net interest rate swap designate fair value hedge interest expense net total gain loss relate outstanding interest rate swap designate fair value hedge recognize interest expense net directly offset loss gain underlie hedged item fixedrate debt result net impact interest expense net period present fair value measure fair value hierarchy consist follow level level valuation base unadjusted quote price active market identical asset company ability access level valuation base quote price similar instrument active market quote price identical similar instrument market active modelbase valuation significant input observable market level valuation significant input unobservable market include use judgment company management assumption market participant use price asset liability follow table summarize basis measure certain asset liability carry fair value recur basis consolidated balance sheet december basis fair value measurement quote price active significant significant market observable unobservable identical asset input input million total level level level asset cash equivalent debt security equity security foreign currency contract total asset liabilitie interest rate hedge foreign currency contract contingent consideration total liability form kthe follow table summarize basis measure certain asset liability carry fair value recur basis consolidated balance sheet december basis fair value measurement quote price active significant significant market observable unobservable identical asset input input million total level level level asset cash equivalent time deposit debt security equity security foreign currency contract total asset liabilitie interest rate hedge foreign currency contract contingent consideration total liability fair value time deposit approximate amortized cost short maturity instrument fair value availableforsale debt security determine base price obtain commercial pricing service availableforsale equity security consist investment fair value determine publish market price unit multiply number unit hold consideration transaction cost derivative enter company value publicize spot curve interest rate hedge publicize forward curve foreign currency contract fair value measurement contingent consideration liability determine base significant unobservable input include discount rate estimate probability time achieve specify development regulatory commercial milestone estimate future sale acquire product development change fair value contingent consideration liability result change number input include discount rate probability achieve milestone time require achieve milestone estimate future sale significant judgment employ determine appropriateness input change input describe material impact company financial position result operation give period december basis point increasedecrease assume discount rate decreasedincrease value contingent consideration liability approximately million additionally december percentage point increasedecrease assume probability success potential indication increaseddecrease value contingent consideration liability approximately million transfer asset liability fair value measurement level follow table present change fair value contingent consideration liability measure level input year end december million begin balance addition note change fair value recognize net earning milestone payment end balance change fair value recognize net earning record expense net consolidated statement earning addition financial instrument company carry fair value consolidate balance sheet certain financial instrument carry historical cost basis fair value book value approximate fair value basis measure approximate fair value certain financial instrument december show table basis fair value measurement quote price significant significant active market observable unobservable approximate identical asset input input million book value fair value level level level asset investment total asset liability shortterm borrowing current portion longterm debt lease obligation exclude fair value hedge longterm debt lease obligation exclude fair value hedge total liability book value approximate fair value basis measure approximate fair value certain financial instrument december show table basis fair value measurement quote price significant significant active market observable unobservable approximate identical asset input input million book value fair value level level level asset investment total asset liability shortterm borrowing current portion longterm debt lease obligation exclude fair value hedge longterm debt lease obligation exclude fair value hedge total liability investment primarily consist cost method investment company take consideration recent transaction financial information investee represent level basis fair value measurement fair value shortterm borrowing approximate carry value short maturity instrument fair value longterm debt exclude fair value hedge term loan determine publish market price debt instrument consideration transaction cost represent level basis fair value measurement fair value term loan determine base discount cash flow analysis quote market rate represent level basis fair value measurement counterpartie financial instrument consist select major international financial institution form kavailableforsale security substantially company investment debt equity security classify availableforsale debt security classify shortterm million december million december longterm debt security mature primarily year estimate fair value availableforsale security base price obtain commercial pricing service follow table summarize availableforsale security type december gross unrealize million amortize cost gain loss fair value asset back security corporate debt security debt security equity security total follow table summarize availableforsale security type december gross unrealize million amortize cost gain loss fair value asset back security corporate debt security debt security equity security total abbvie otherthantemporary impairment december net realize gain million net realize gain insignificant concentration risk company invest excess cash time deposit money market fund debt security diversify concentration cash different financial institution company establish credit exposure limit monitor concentration credit risk associate financial institution deposit functional currency company venezuela operation dollar hyperinflationary status venezuelan economy quarter consideration decline economic condition venezuela decline transaction settle official rate abbvie determine net monetary asset denominate venezuelan bolivar vef long expect settle official rate vef dollar divisa complementaria dicom rate quarter abbvie record charge million net foreign exchange loss revalue bolivardenominate net monetary asset dicom rate effect approximately vef dollar december abbvie net monetary asset venezuela insignificant abbvie continue business foreign government certain country include greece portugal italy spain historically experience challenge credit economic condition substantially abbvie trade receivable greece portugal italy spain government health system outstanding governmental receivables country net allowance doubtful account total million december million december company continue business foreign government certain oilexporting country experience deterioration economic condition include saudi arabia russia result delay collection receivables outstanding governmental receivables relate saudi arabia net allowance doubtful account million december million december outstanding governmental receivables relate russia net allowance doubtful account million december million december global economic condition customerspecific factor require company periodically reevaluate collectability receivables company potentially incur credit loss total net account receivable wholesaler account december december substantially abbvie net revenues united states wholesaler humira adalimumab abbvie single large product account approximately abbvie total net revenue note postemployment benefit abbvie sponsor pension postemployment benefit plan include define benefit define contribution termination indemnity plan cover employee worldwide addition abbvie provide medical benefit primarily eligible retiree united states puerto rico postretirement benefit plan net obligation plan reflect consolidated balance sheet december abbvie principal domestic define benefit plan abbvie pension plan abbvie voluntary contribution million plan abbvie plan voluntary contribution define benefit plan excess million follow table summarize benefit plan information global abbviesponsore define benefit postemployment plan define postemployment benefit plan plan year end december millions project benefit obligation begin period service cost interest cost employee contribution actuarial loss benefit pay primarily foreign currency translation adjustment end period fair value plan asset begin period actual return plan asset company contribution employee contribution benefit pay primarily foreign currency translation adjustment end period fund status end period amount recognize consolidated balance sheet asset account payable accrue liability longterm liability net obligation actuarial loss net prior service cost credit accumulate comprehensive loss form kthe project benefit obligation pbo table include billion december billion december relate international define benefit plan plan reflect table accumulate benefit obligation abo billion december billion december plan reflect table abo exceed plan asset december abo billion pbo billion aggregate plan asset billion amount recognize comprehensive loss follow table summarize pretax gain loss include comprehensive loss year end december millions define benefit plan actuarial loss gain amortization actuarial loss prior service cost foreign exchange gain loss total pretax loss gain recognize comprehensive loss postemployment plan actuarial loss gain amortization actuarial loss prior service cost credit total pretax loss gain recognize comprehensive loss pretax actuarial loss prior service cost include aoci december expect recognize net periodic benefit cost million define benefit plan million postemployment plan net periodic benefit cost year end december millions define benefit plan service cost interest cost expect return plan asset amortization actuarial loss prior service cost net periodic benefit cost postemployment plan service cost interest cost amortization actuarial loss prior service cost net periodic benefit cost weightedaverage assumption determine benefit obligation measurement date december define benefit plan discount rate rate compensation increase postemployment plan discount rate assumption calculate december measurement date benefit obligation calculation net periodic benefit cost weightedaverage assumption determine net periodic benefit cost year end december define benefit plan discount rate determine service cost discount rate determine interest cost expect longterm rate return plan asset expect rate change compensation postemployment plan discount rate determine service cost discount rate determine interest cost effective december abbvie elect change method use estimate service interest cost component net periodic benefit cost historically abbvie estimate service interest cost component expense utilize single weightedaverage discount rate derive yield curve measure benefit obligation beginning period late abbvie elect utilize yield curve approach estimation component apply specific spot rate yield curve determination benefit obligation relevant project cash flow abbvie elect change provide precise measurement service interest cost improve correlation project benefit cash flow correspond spot yield curve rate abbvie account change prospectively change accounting estimate inseparable change accounting principle change reduce abbvie net periodic benefit cost approximately million change effect expense affect measurement abbvie total benefit obligation december postretirement health care obligation remeasurement company assume pre post annual rate increase capita cost cover health care benefit rate assume decrease gradually remain level purpose measure postretirement health care cost company assume pre post annual rate increase capita cost cover health care benefit rate assume decrease gradually remain level assume health care cost trend rate significant effect amount report health care plan december percentage point change assume health care cost trend rate follow effect percentage point year end december million bracket denote reduction increase decrease service cost interest cost project benefit obligation form kdefine benefit pension plan asset basis fair value measurement quote price significant significant active market observable unobservable identical asset input input december millions level level level equitie large capa mid capb internationalc fix income security government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real asset otherf total total asset measure nav fair value plan asset basis fair value measurement quote price significant significant active market observable unobservable identical asset input input december millions level level level equitie large capa mid capb internationalc fix income security government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real asset otherf total total asset measure nav fair value plan asset mix index fund actively manage equity account benchmarke large cap indice b mix index fund actively manage equity account benchmarke mid cap indice c mix index fund actively manage equity account benchmarke nonus equity index develop emerge market security hold actively manage account index fund mutual fund e primarily fund global mandate flexibility allocate capital broadly wide range asset class strategy include limited equity fix income commodity financial future currency security objective outperform agree benchmark specific return volatility target f investment cash cash equivalent equities register investment company quote price value publish market price fix income security value significant observable input quote price obtain independent financial service industryrecognize vendor investment hold pool investment fund common collective trust limited partnership value net asset value nav practical expedient estimate fair value nav provide fund administrator base value underlie asset own fund minus liability investment mix equity security fix income asset allocation strategy base achieve desire return balance high return volatile equity security low return volatile fix income security investment allocation establish plan generally range market industry sector capitalization size case fix income security maturity credit quality target investment allocation abbvie pension plan equity security fix income security asset allocation strategy holding know significant concentration risk plan asset abbvie pension plan plan expect return plan asset assumption plan base management expectation longterm average rate return achieve underlying investment portfolio establish assumption management consider historical expect return asset class plan invest current economic capital market condition expect benefit payment follow table summarize total benefit payment expect pay plan participant include payment fund plan company asset define postemployment year end december million benefit plan plan define contribution plan abbvie principal define contribution plan abbvie saving plan abbvie record expense million million million relate plan abbvie provide certain postemployment benefit primarily salary continuation arrangement qualify employee accrue related cost service live employee form knote equity stockbased compensation abbvie grant stockbase award eligible employee pursuant abbvie incentive stock program isp provide different form benefit include nonqualified stock option rsas rsus performancebase award isp million share abbvie common stock reserve issuance award abbvie employee isp facilitate assumption certain award grant abbotts incentive stock program adjust convert abbott abbvie stockbased award result abbvie separation abbott abbvie measure compensation expense stockbase award base grant date fair value award estimate number award expect vest forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate compensation cost stockbase award amortize service period shorter vest period employee retirement eligible retirement eligible employee generally age old year service stockbase compensation expense principally relate award issue pursuant isp summarize follow year end december million cost product sell research development sell general administrative pretax compensation expense tax benefit aftertax compensation expense stockbase compensation expense year end december include postcombination impact relate stemcentrx option note additional information relate stemcentrx acquisition realize excess tax benefit associate stockbase compensation total million million million begin excess tax benefit associate stockbased award recognize statement earning award vest settle stockholder equity result adoption new accounting pronouncement note additional information adoption new accounting pronouncement stock option stock option award pursuant isp typically contractual term year generally vest onethird increment threeyear period exercise price equal market value date grant fair value determine blackschole model weightedaverage grantdate fair value stock option grant follow table summarize abbvie stock option activity weight weight average average remain aggregate option thousand aggregate intrinsic value million option exercise price life year intrinsic value outstanding december grant exercise lapsed outstanding december exercisable december total intrinsic value option exercise million million million total fair value option vest million june abbvie issue stock option million abbvie share holder unveste stemcentrx option result conversion option connection stemcentrx acquisition option fairvalue lattice valuation model note additional information relate stemcentrx acquisition december million unrecognized compensation cost relate stock option expect recognize expense approximately year rsas rsus performance share rsus award employee senior executive key employee pursuant isp generally vest onethird increment year period recipient rsus entitle receive dividend equivalent dividend declare pay rsu vest period majority equity award abbvie grant senior executive key employee isp performancebase award grant consist rsas rsus extent necessary global employee generally vest onethird increments threetofive year period vest contingent abbvie achieve minimum annual return equity roe recipient entitle receive dividend dividend equivalent rsus dividend declare pay award vest period abbvie redesign certain aspect longterm incentive program result equity award grant senior executive key employee consist combination performanceveste rsus performance share performanceveste rsus potential vest onethird increment threeyear performance period base abbvie roe relative define peer group pharmaceutical biotech life science company recipient receive share abbvie common stock vest award performance share potential vest threeyear performance period earn base abbvie ep achievement abbvie total stockholder return tsr market condition relative define peer group pharmaceutical biotech life science company dividend equivalent performanceveste rsus performance share accrue performance period payable vest extent share earn weightedaverage grantdate fair value rsas rsus performance share generally determine base number sharesunit grant quote price abbvie common stock date grant weightedaverage grantdate fair value performance share tsr market condition determine monte carlo simulation model form kthe follow table summarize abbvie rsa rsu performance share activity weightedaverage share unit thousand share unit grant date fair value outstanding december grant vest forfeited outstanding december fair market value rsas rsus performance share applicable vested million million million december million unrecognized compensation cost relate rsas rsus performance share expect recognize expense approximately year cash dividend follow table summarize quarterly cash dividend declare year end december date declare payment date dividend share date declare payment date dividend share february abbvie announce board director declare increase company quarterly cash dividend share share beginning dividend payable stockholder record april stock repurchase program company stock repurchase authorization permit purchase abbvie share time time openmarket private transaction management discretion program time limit discontinue time share repurchase program record acquisition cost include related expense available general corporate purpose abbvie board director authorize increase exist stock repurchase program billion april anticipation execute asr connection stemcentrx acquisition billion march anticipation execute asr connection pharmacyclic acquisition follow table show detail abbvie asr transaction share millions repurchase amount billion initial delivery final delivery execution date purchase share share relate acquisition pharmacyclic stemcentrx february abbvie board director authorize billion increase abbvie exist stock repurchase program abbvie remain share repurchase authorization billion december february abbvie board director authorize new billion stock repurchase program supersede abbvie previous stock repurchase program new stock repurchase program permit purchase abbvie share time time openmarket private transaction include accelerated share repurchase management discretion program time limit discontinue time addition asr abbvie repurchase open market approximately million share billion million share billion million share billion accumulate comprehensive loss follow table summarize change component aoci net tax foreign pension currency net investment post translation hedge employment marketable security cash flow hedge million bracket denote loss adjustment activity benefit activity activity total balance december comprehensive income loss reclassification net loss gain reclassify accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income loss reclassification net loss gain reclassify accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income loss reclassification net loss gain reclassify accumulated comprehensive loss net currentperiod comprehensive income loss balance december abbvie reclassify million historical currency translation loss aoci relate liquidation certain foreign entity follow enactment tax reform loss include net foreign exchange loss consolidate statement earning relate income tax impact comprehensive loss include foreign currency translation adjustment total gain million principally impact strengthen euro translation company eurodenominate asset comprehensive loss include foreign currency translation adjustment total loss million principally impact weaken euro translation company eurodenominate asset comprehensive loss include foreign currency translation adjustment total loss million principally drive impact weaken euro translation company eurodenominate asset form kthe table present impact abbvie consolidated statement earning significant amount reclassify component accumulate comprehensive loss year end december million bracket denote gain pension postemployment benefit amortization actuarial loss othera tax benefit total reclassification net tax cash flow hedging activity loss gain designate cash flow hedgesb tax expense benefit total reclassification net tax amount include computation net periodic benefit cost note b amount include cost product sell note addition common stock abbvie authorize capital include million share prefer stock par value december share prefer stock issue outstanding note income taxis earning income tax expense year end december million domestic foreign total earning income tax expense income tax expense year end december million current domestic foreign total current taxis defer domestic foreign total defer taxis total income tax expense impact relate tax reform tax cut job act act sign law december result significant change corporate tax system act reduce federal corporate tax rate require company pay onetime transition tax mandatory deem repatriation earning certain foreign subsidiary previously untaxe create new taxis certain foreign source earning change effective begin prior enactment act company provide deferred income taxis undistribute earning foreign subsidiary indefinitely reinveste continued use foreign operation provision act require onetime deem repatriation earning foreign subsidiary company long consider earning indefinitely reinveste transition tax expense onetime mandatory repatriation previously untaxe earning foreign subsidiary billion generally payable annual installment additionally company remeasure certain defer tax asset liability base tax rate expect reverse future net tax benefit tax reform remeasurement defer taxis relate act foreign tax law change billion give complexity act anticipate guidance treasury implement act company analysis account tax effect act preliminary direct result act company record billion transition tax expense billion net tax benefit defer tax remeasurement amount provisional estimate company fully complete analysis calculation foreign earning subject transition tax analysis certain aspect act result adjustment remeasurement defer tax balance completion analysis estimate adjust income tax expense consolidated statement earning effective tax rate reconciliation year end december statutory tax rate effect foreign operation tax credit impact relate tax reform tax law change related foreign currency net effective tax rate effective income tax rate fluctuate year year allocation company taxable earning jurisdiction certain discrete factor event year include change tax law acquisition collaboration effective income tax rate differ statutory tax rate principally change enact tax rate law benefit foreign operation reflect impact low income tax rate location outside united states tax incentive puerto rico foreign tax jurisdiction business development activity cost repatriation decision effective tax rate period reflect benefit tax credit principally relate research development credit orphan drug tax credit puerto rico excise tax credit puerto rico excise tax credit relate legislation enact puerto rico assess excise tax certain product manufacture puerto rico tax levy gross inventory purchase entities puerto rico include cost product sell consolidated statement earning majority tax creditable income tax purpose effective income tax rate include impact relate tax reform addition company recognize net tax benefit million relate resolution tax position pertain prior year effective income tax rate include additional expense million relate recognition tax effect regulation issue internal revenue service december change determination taxability foreign currency gain loss relate certain foreign operation effective income tax rate include tax benefit million reduction state valuation allowance form kdeferre tax asset liability december millions defer tax asset compensation employee benefit accrual reserve chargeback rebate defer revenue net operating loss credit carryforward total defer tax asset valuation allowance total net defer tax asset defer tax liability excess book basis tax basis intangible asset excess book basis tax basis investment total defer tax liability net defer tax liability decrease defer tax asset liability primarily enactment tax reform reduce federal corporate tax rate create territorial tax system generally allow repatriation future foreign sourced earning incur additional taxis act create minimum tax certain foreign source earning taxability foreign source earning applicable tax rate dependent future event company evaluate accounting policy minimum tax foreign source earning provisional estimate tax effect act report basis minimum tax recognize tax expense year incur period expense december gross state net operating loss billion tax credit carryforwards million state tax carryforward expire december foreign net operating loss carryforward million foreign net operating loss carryforward million expire remain expiration period company valuation allowance million december million december principally relate state net operating loss credit carryforward expect realize current income taxis receivable billion december million december include prepay expense consolidate balance sheet unrecognize tax benefit year end december million begin balance increase current year tax position increase prior year tax position decrease prior year tax position settlement lapse statute limitation end balance abbvie abbott enter tax sharing agreement effective date separation provide abbott liable indemnify abbvie income tax liability period prior separation abbvie responsible unrecognized tax benefit relate interest penalty period separation instance exist entity transfer abbvie separation recognize net potential tax benefit impact company effective tax rate billion billion unrecognized tax benefit record table december abbvie indemnify approximately million increase current year tax position table include amount related federal state international tax item include provisional estimate remeasurement unrecognized tax benefit relate earning foreign subsidiary follow enactment tax reform increase prior year tax position table include amount relate federal state international item prior position acquire business development activity year uncertain tax position generally include longterm liability consolidated balance sheet abbvie recognize interest penalty relate income tax matter income tax expense consolidated statement earning abbvie recognize gross income tax expense million million million interest penalty relate income tax matter abbvie accrual payment gross interest penalty million december million december million december company routinely audit tax authority significant jurisdiction number audits currently underway reasonably possible month uncertain tax position settle result decrease gross unrecognized tax benefit potential resolution federal state foreign examination expiration statute limitation company gross unrecognized tax benefit balance change month million significant federal state local international matter conclude year company believe adequate provision income tax uncertainty note legal proceeding contingency abbvie subject contingency claim legal proceeding investigation product liability intellectual property commercial security matter arise normal course business loss contingency provision record probable loss management well estimate loss good estimate minimum loss contingency probable range record record accrual balance litigation approximately million december approximately million december initiation new legal proceeding change status exist proceeding result change estimate loss accrue abbvie feasible predict outcome proceeding exposure certainty management believe ultimate disposition material adverse effect abbvie consolidated financial position result operation cash flow subject certain exception specify separation agreement abbott abbvie abbvie assume liability control pende threatened legal matter relate business include liability claim legal proceeding relate product business discontinue prior distribution assume retain liability indemnify abbott liability arise result assume legal matter pende lawsuit file unimed pharmaceuticals inc solvay pharmaceuticals inc company abbott acquire february know abbvie product llc consolidated pretrial purpose united states district court northern district georgia multidistrict litigation mdl rules androgel antitrust litigation mdl case bring private plaintiff federal trade commission ftc generally allege solvay patent litigation involve androgel sham litigation patent litigation settlement agreement relate agreement generic company violate federal antitrust law plaintiff generally seek monetary damage andor injunctive relief attorney fee case include individual plaintiff lawsuit b purport class action c federal trade commission v actavis inc et al follow district court dismissal plaintiff claim appellate proceeding lead reinstatement claim patent litigation settlement proceed district court form klawsuit pende abbvie generally allege patent litigation settlement involve niaspan enter kos pharmaceuticals inc company acquire abbott presently subsidiary abbvie generic company violate federal state antitrust law state unfair deceptive trade practice unjust enrichment law plaintiff generally seek monetary damage andor injunctive relief attorney fee lawsuit consist individual plaintiff lawsuit consolidated purport class action bring name direct purchaser niaspan bring name endpayer purchaser niaspan case consolidate pretrial proceeding united states district court eastern district pennsylvania mdl rule niaspan antitrust litigation mdl october state california file lawsuit niaspan patent litigation settlement orange county superior court assert claim unfair competition provision california business profession code seek injunctive relief restitution civil penalty attorney fee september ftc file suit united states district court eastern district pennsylvania abbvie allege patent litigation generic company androgel sham litigation patent litigation settlement generic company violate federal antitrust law ftc complaint seek monetary damage injunctive relief court dismiss ftc claim patent litigation settlement march state louisiana file lawsuit state louisiana v fournier industrie et sante et al abbvie abbott affiliate abbott entities louisiana state court plaintiff allege patent application patent litigation file allege conduct early related drug tricor violate louisiana state antitrust unfair trade practice law lawsuit seek monetary damage attorney fee november putative class action lawsuit medical mutual ohio v abbvie inc et al file manufacturer testosterone replacement therapie trt include abbvie united states district court northern district illinois behalf insurance company health benefit provider party payer pay trt include androgel claim assert include violation federal rico act state consumer fraud deceptive trade practice law complaint seek monetary damage injunctive relief product liability case pende plaintiff generally allege abbvie manufacturer trt adequately warn risk certain injury primarily heart attack stroke blood clot approximately claim consolidated pretrial purpose united states district court northern district illinois mdl rule testosterone replacement therapy product liability litigation mdl approximately claim pende state court plaintiff generally seek compensatory punitive damage july jury united states district court northern district illinois reach verdict case try jury find abbvie plaintiff strict liability negligence claim plaintiff plaintiff fraud claim jury award compensatory damage award plaintiff million punitive damage december court vacate jurys verdict punitive damage award fraud claim order new trial claim second case jury united states district court northern district illinois reach verdict abbvie august claim subject posttrial proceeding case jury united states district court northern district illinois reach verdict abbvie october strict liability plaintiff remain claim award compensatory damage million punitive damage subject posttrial proceeding separate case jury united states district court northern district illinois reach verdict abbvie january claim product liability case pende plaintiff generally allege abbvie adequately warn risk certain injury primarily birth defect arise use depakote ninety percent approximately claim pende united states district court southern district illinois rest pende federal state court plaintiff generally seek compensatory punitive damage november individual file putative class action lawsuit rubinstein et al v gonzalez et al behalf purchaser seller certain shire plc shire securities june october abbvie chief executive officer united states district court northern district illinois allege defendant andor responsible material misstatement violation federal security law connection abbvie propose transaction shire june lawsuit elliott associates lp et al v abbvie inc file investment fund abbvie cook county illinois circuit court allege abbvie misrepresentation omission connection propose transaction shire similar lawsuit file july september abbvie instance chief executive officer court additional investment fund plaintiff seek compensatory punitive damage shareholder derivative lawsuit ellis v gonzalez et al file delaware chancery court allege abbvie director breach fiduciary duty connection statement shire transaction lawsuit seek unspecified compensatory damage abbvie relief beginning patent trial appeal board patent trademark office pto institute inter parte review proceeding bring coherus biosciences boehringer ingelheim relate abbvie patent cover method treatment rheumatoid arthritis adalimumab proceeding pto review validity patent issue decision invalidity june july abbvie appeal decision pende court appeal federal circuit march abbvie file lawsuit abbvie inc v novartis vaccine diagnostic inc grifol worldwide operations ltd united states district court northern district california novartis vaccine grifol worldwide seek declaratory judgment hcvrelate patent license abbvie invalid abbvie seek enforce certain patent right relate adalimumab drug abbvie sell trademark humira case file united states district court district delaware august abbvie allege boehringer ingelheim international gmbhs boehringer ingelheim pharmaceutical incs boehringer ingelheim fremont inc propose biosimilar adalimumab product infringe certain abbvie patent abbvie seek declaratory injunctive relief pharmacyclic llc wholly own subsidiary abbvie seek enforce patent right relate ibrutinib capsule drug pharmacyclic sell trademark imbruvica case file united states district court district delaware february pharmacyclic allege fresenius kabi usa llc fresenius kabi usa inc fresenius kabi oncology limited propose generic ibrutinib product infringe pharmacyclic patent pharmacyclic seek declaratory injunctive relief janssen biotech inc global collaboration pharmacyclic concern development marketing imbruvica coplaintiff suit note segment geographic area information abbvie operate business segmentpharmaceutical product substantially abbvie net revenues united states wholesaler outside united states product sell primarily health care provider distributor depend market serve follow table detail abbvie worldwide net revenue year end december millions humira imbruvica hcv lupron creon synagi synthroid androgel kaletra sevoflurane duodopa total net revenue form knet revenue external customer geographic area base product shipment destination follow year end december millions united states germany united kingdom japan france canada spain italy brazil netherlands country total net revenue longlive asset primarily net property equipment geographic area follow december millions united states puerto rico europe total longlive asset note quarterly financial datum unaudite million share datum quarter net revenue gross margin net earningsa basic earning share dilute earning share cash dividend declare common share second quarter net revenue gross margin net earningsb basic earning share dilute earning share cash dividend declare common share quarter net revenue gross margin net earningsc basic earning share dilute earning share cash dividend declare common share fourth quarter net revenue gross margin net earningsd basic earning share dilute earning share cash dividend declare common share quarter result include aftertax cost million relate change fair value contingent consideration liability quarter result include net foreign exchange loss million relate devaluation abbvie net monetary asset denominate venezuelan bolivar b second quarter result include aftertax charge million increase litigation reserve aftertax cost million relate change fair value contingent consideration liability second quarter result include aftertax cost total million relate acquisition stemcentrx bi compound amortization acquisition date fair value stepup inventory relate acquisition pharmacyclic c quarter result include aftertax cost million relate change fair value contingent consideration liability quarter result include aftertax cost million relate change fair value contingent consideration liability fourth quarter result impact net charge relate december enactment tax cut job act include tax charge billion relate onetime mandatory repatriation previously untaxe earning foreign subsidiary partially offset aftertax benefit billion form kremeasurement net defer tax liability relate impact additional aftertax cost impact fourth quarter result include million intangible asset impairment charge million charge increase litigation reserve million result enter global strategic collaboration alector inc million relate change fair value contingent consideration liability cost partially offset aftertax benefit million tax audit settlement fourth quarter result include aftertax cost total million associate tax law change regulation issue fourth quarter revise treatment foreign currency translation gain loss certain operation aftertax cost total million relate change fair value contingent consideration liability report independent register public accounting firm stockholder board directors abbvie inc opinion financial statement audit accompany consolidated balance sheet abbvie inc subsidiary company december relate consolidated statement earning comprehensive income equity cash flow year period end december relate note collectively refer financial statement opinion financial statement present fairly material respect consolidate financial position company december consolidate result operation cash flow year period end december conformity generally accept accounting principle audit accordance standard public company accounting oversight board united states pcaob company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion ernst young llp serve company auditor chicago illinois february form kitem change disagreement accountant account financial disclosure item control procedure disclosure control procedure internal control financial reporting evaluation disclosure control procedure chief executive officer richard gonzalez chief financial officer william j chase evaluate effectiveness abbvie disclosure control procedure end period cover report conclude abbvie disclosure control procedure effective ensure information abbvie require disclose report file submit securities exchange commission securities exchange act record process summarize report time period specify commission rule form ensure information require disclose abbvie report file submit securities exchange act accumulate communicate abbvie management include principal executive officer principal financial officer appropriate allow timely decision require disclosure change internal control financial reporting change abbvie internal control financial reporting define rule f securities exchange act materially affect reasonably likely materially affect abbvie internal control financial reporting quarter end december inherent limitation effectiveness control abbvie management include chief executive officer chief financial officer expect abbvie disclosure control internal control financial reporting prevent detect error fraud control system matter design operate provide reasonable absolute assurance control system objective meet design control system reflect fact resource constraint benefit control consider relative cost inherent limitation control system evaluation control provide absolute assurance misstatement error fraud occur control issue instance fraud detect inherent limitation include reality judgment decisionmake faulty breakdown occur simple error mistake control circumvent individual act person collusion people management override control design system control base certain assumption likelihood future event assurance design succeed achieve state goal potential future condition projection evaluation control effectiveness future period subject risk time control inadequate change condition deterioration degree compliance policy procedure management annual report internal control financial reporting management abbvie responsible establish maintain adequate internal control financial reporting term define rule af securities exchange act abbvie internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle unite states internal control system matter design inherent limitation system determine effective provide reasonable assurance respect financial statement preparation report management assess effectiveness abbvie internal control financial reporting december make assessment management criterion set forth committee sponsor organization treadway commission coso internal controlintegrate framework framework base assessment management conclude abbvie maintain effective internal control financial reporting december base coso criterion effectiveness abbvie internal control financial reporting december audit ernst young llp independent register public accounting firm state attestation report express unqualified opinion effectiveness abbvie internal control financial reporting december report independent register public accounting firm report abbvie independent register public accounting firm relate assessment effectiveness internal control financial reporting include form kreport independent register public accounting firm stockholder board directors abbvie inc opinion internal control financial reporting audit abbvie inc subsidiary internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework coso criterion opinion abbvie inc subsidiary company maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states pcaob consolidated balance sheet abbvie inc subsidiary december relate consolidated statement earning comprehensive income equity cash flow year period end december relate note company report date february express unqualified opinion thereon basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management annual report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate ernst young llp chicago illinois february item b information form kpart iii item director executive officer corporate governance incorporate reference information concern director nominee board director committeescommittee board director section beneficial ownership report compliance procedure recommendation nomination director transaction business annual meeting include abbvie inc proxy statement definitive proxy statement file march incorporate reference text find caption executive officer registrant abbvie code business conduct require business activity conduct compliance applicable law regulation ethical principle value director officer employee abbvie require read understand abide requirement code business conduct applicable abbvie code business conduct available corporate governance section abbvie investor relation website wwwabbvieinvestorcom waiver code business conduct director executive officer abbvie audit committee abbvie disclose amendment waiver provision code conduct principal executive officer principal financial officer principal accounting officer controller person perform similar function website business day follow date amendment waiver addition abbvie disclose waiver code business conduct executive officer director website abbvie chief ethic compliance officer report chief executive officer public policy committee chief ethic compliance officer responsible overseeing administer monitor abbvie compliance program item executive compensation material include abbvie inc proxy statement heading director compensation executive compensation compensation committee report incorporate reference definitive proxy statement file march item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information follow table present information december abbvie equity compensation plan abbvie common stock authorize issuance c number security remaining number b available security weight future issuance issue average exercise equity exercise price compensation outstanding outstanding plan exclude option option security warrant warrant reflect plan category right right column equity compensation plan approve security holder equity compensation plan approve security holder total include share issuable abbvie incentive stock program pursuant award grant abbott adjust abbvie award connection abbvie separation abbott weightedaverage exercise price include outstanding restricted stock unit restrict stock award performance share exercise price exclude share issuable exercise stock option pursuant right grant stemcentrx equity incentive plan assume abbvie consummation acquisition stemcentrx inc december option remain outstanding plan option weightedaverage exercise price award grant plan b information concern security ownership incorporate reference material head security ownershipsecuritie ownership executive officer directors abbvie inc proxy statement definitive proxy statement file march item certain relationship relate transaction director independence material include abbvie inc proxy statement heading board director committee corporate governance material procedure approval related person transaction incorporate reference definitive proxy statement file march item principal accounting fee service material include abbvie inc proxy statement heading audit fee nonaudit fee policy audit committee preapproval audit permissible nonaudit services independent register public accounting firm incorporate reference definitive proxy statement file march form kpart iv item